Kazia Therapeutics Limited (KZIA) 20-F 26 Oct 23 2023 FY Annual report (foreign) Financial data

Cover

Cover - shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	Kazia Therapeutics Limited
Entity Central Index Key	0001075880
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Voluntary Filers	No
Entity Shell Company	false
Entity Interactive Data Current	Yes
Document Transition Report	false
Document Annual Report	true
Document Shell Company Report	false
Entity Address, Address Line One	Three International Towers Level 24, 300 Barangaroo Avenue
Entity Address, City or Town	Sydney
Entity Address, Postal Zip Code	2000
Entity Address Country	AU
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Entity Common Stock, Shares Outstanding	228,029,114
Entity Incorporation, State or Country Code	C3
Entity File Number	0-29962
Title of 12(b) Security	American Depositary Shares, each representing tenOrdinary Shares*
Trading Symbol	KZIA
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Auditor Name	BDO Audit Pty Ltd	GRANT THORNTON AUDIT PTY LTD
Auditor Firm ID	2256	2233
Auditor Location	Sydney, Australia	Sydney, Australia
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Karen Krumeich
Contact Personnel Email Address	Karen.Krumeich@kaziatherapeutics.com
Entity Address, Address Line One	Three International Towers Level 24, 300 Barangaroo Avenue
Entity Address, City or Town	Sydney
Entity Address, Postal Zip Code	2000
Entity Address Country	AU
Country Region	61
City Area Code	2
Local Phone Number	9472-4101

Consolidated statements of prof

Consolidated statements of profit or loss and other comprehensive income - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Revenue and other income
Revenue from continuing operations	$ 0	$ 0	$ 15,183,000
Other income	1,000	25,000	2,000
Finance income — bank interest	22,000	2,000	42,000
Expenses
Research and development expense	(15,564,000)	(20,169,000)	(14,541,000)
General and administrative expense	(8,583,000)	(5,113,000)	(7,020,000)
Gain/(loss) on remeasurement of contingent consideration	3,388,000	0	(2,570,000)
Commercialisation	0	(127,000)	0
Loss before income tax benefit from continuing operations	(20,736,000)	(25,382,000)	(8,904,000)
Income tax benefit	271,000	368,000	484,000
Loss after income tax benefit for the year	(20,465,180)	(25,014,055)	(8,420,000)
Items that may be reclassified subsequently to profit or loss
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax	110,000	35,000	2,000
Other comprehensive income for the year, net of tax	110,000	35,000	2,000
Total comprehensive income for the year	(20,355,000)	(24,979,000)	(8,418,000)
Loss for the year is attributable to:
Owners of Kazia Therapeutics Limited	(20,465,000)	(25,014,000)	(8,420,000)
Loss after income tax benefit for the year	(20,465,180)	(25,014,055)	(8,420,000)
Total comprehensive income for the year is attributable to:
Owners of Kazia Therapeutics Limited	(20,355,000)	(24,979,000)	(8,418,000)
Total comprehensive income for the year	$ (20,355,000)	$ (24,979,000)	$ (8,418,000)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share	$ (0.1123)	$ (0.1888)	$ (0.0716)
Diluted earnings per share	(0.1123)	(0.1888)	(0.0716)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share	(0.1123)	(0.1888)	(0.0716)
Diluted earnings per share	$ (0.1123)	$ (0.1888)	$ (0.0716)

Consolidated statements of fina

Consolidated statements of financial position - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Current assets
Cash and cash equivalents	$ 5,241,197	$ 7,361,112	$ 27,587,000
Trade and other receivables	3,899,000	91,000	84,000
Other assets	1,632,000	1,997,000	1,720,000
Total current assets	10,772,000	9,449,000	29,391,000
Non-current assets
Trade and other receivables	43,000	7,301,000	6,694,000
Intangibles	17,269,000	19,139,000	21,008,000
Total non-current assets	17,312,000	26,440,000	27,702,000
Total assets	28,084,000	35,889,000	57,093,000
Current liabilities
Trade and other payables	4,329,000	3,759,000	4,933,000
Borrowings	1,796,000	1,841,000	0
Employee benefits	690,000	369,000	229,000
Contingent consideration	750,000	759,000	791,000
Total current liabilities	7,565,000	6,728,000	5,953,000
Non-Current liabilities
Deferred tax	2,289,000	2,560,000	2,928,000
Employee benefits	59,000	117,000	55,000
Contingent consideration	6,121,000	8,209,000	10,304,000
Total non-current liabilities	8,469,000	10,886,000	13,287,000
Total liabilities	16,034,000	17,614,000	19,240,000
Net assets	12,050,000	18,275,000	37,853,000
Equity
Contributed equity	97,452,246	84,480,249	80,290,000
Other contributed equity	0	0	464,000
Reserves	3,681,000	2,412,000	1,301,000
Accumulated losses	(89,083,000)	(68,617,000)	(44,202,000)
Equity attributable to the owners of Kazia Therapeutics Limited	12,050,000	18,275,000	37,853,000
Total equity	$ 12,050,000	$ 18,275,000	$ 37,853,000

Statements of changes in equity

Statements of changes in equity - AUD ($)	Total	Contributed equity [member]	Other Contributed equity [member]	Reserves [member]	Accumulated Losses [member]	Non-controlling interests [member]
Beginning Balance at Jun. 30, 2020	$ 14,125,000	$ 48,781,000	$ 464,000	$ 1,066,000	$ (36,186,000)
Loss after income tax expense for the year (restated)	(8,420,000)				(8,420,000)
Other comprehensive income for the year, net of tax	2,000			2,000
Total comprehensive income for the year (restated)	(8,418,000)			2,000	(8,420,000)
Transactions with owners in their capacity as owners:
Contributions of equity	32,909,000	32,909,000
Share issue costs	(1,673,000)	(1,673,000)
Share based payment	637,000			637,000
Shares issued	273,000	273,000		(80,000)	80,000
Expired options				(324,000)	324,000
Ending balance at Jun. 30, 2021	37,853,000	80,290,062	464,000	1,301,000	(44,202,000)
Loss after income tax expense for the year (restated)	(25,014,055)				(25,014,000)
Other comprehensive income for the year, net of tax	35,000			35,000
Total comprehensive income for the year (restated)	(24,979,000)			35,000	(25,014,000)
Transactions with owners in their capacity as owners:
Share issue costs	(493,000)	(493,000)
Immaterial reclassification				(434,000)	434,000
Share based payment	1,674,000			1,674,000
Shares issued	4,202,000	4,202,000
Issue of shares on exercise of options	17,000	17,000		(6,000)	6,000
Conversion of convertible note		464,000	(464,000)
Expired options				(159,000)	159,000
Ending balance at Jun. 30, 2022	18,275,000	84,480,249		2,412,000	(68,617,000)
Loss after income tax expense for the year (restated)	(20,465,180)				(20,465,000)
Other comprehensive income for the year, net of tax	110,000			110,000
Total comprehensive income for the year (restated)	(20,355,000)			110,000	(20,465,000)
Transactions with owners in their capacity as owners:
Share issue costs	(401,000)	(401,000)
Share based payment	1,159,000			1,159,000
Shares issued	13,373,000	13,373,000
Ending balance at Jun. 30, 2023	$ 12,050,000	$ 97,452,246		$ 3,681,000	$ (89,083,000)

Consolidated statements of cash

Consolidated statements of cash flows - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Loss after income tax expense for the year	$ (20,465,180)	$ (25,014,055)	$ (8,420,000)
Adjustments for:
Depreciation and amortisation	1,869,000	1,869,000	1,265,000
Share-based payments	1,159,000	1,675,000	637,000
Foreign exchange differences	46,000	(2,154,000)	428,000
Gain on remeasurement of contingent consideration	(2,097,000)		2,570,000
Cash flows from used in operations before changes in working capital	(19,488,000)	(23,624,000)	(3,520,000)
Change in operating assets and liabilities:
Increase/(decrease) in trade and other receivables	3,450,000	(7,000)	(5,027,000)
Increase/(decrease) in prepayments	365,000	(277,000)	(1,182,000)
Increase/(decrease) in trade and other payables	569,000	(528,000)	1,010,000
Increase in other provisions	264,000	201,000	92,000
Decrease in deferred tax liability	(271,000)	(368,000)	(484,000)
(Decrease)/increase in borrowings	(45,000)	1,841,000
Net cash used in operating activities	(15,156,000)	(22,762,000)	(9,111,000)
Cash flows from investing activities
Payment of milestone relating to contingent consideration		(2,365,000)
Net cash used in investing activities		(2,365,000)
Cash flows from financing activities
Proceeds from issue of shares	12,972,000	3,726,000	28,109,000
Net cash from financing activities	12,972,000	3,726,000	28,109,000
Net (decrease)/increase in cash and cash equivalents	(2,184,000)	(21,401,000)	18,998,000
Cash and cash equivalents at the beginning of the financial year	7,361,112	27,587,000	8,764,000
Effects of exchange rate changes on cash	64,000	1,175,000	(175,000)
Cash and cash equivalents at the end of the financial year	$ 5,241,197	$ 7,361,112	$ 27,587,000

General information

General information	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
General information	Note 1. General information The financial statements cover Kazia Therapeutics Limited (the “Consolidated Entity”) as a consolidated entity which consists of Kazia Therapeutics Limited and its subsidiaries. The financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited’s functional and presentation currency. Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000 The financial statements were authorised for issue, in accordance with a resolution of Directors, on 26 October 2023. The Directors have the power to amend and reissue the financial statements.

Significant accounting policies

Significant accounting policies	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Significant accounting policies	Note 2. Significant accounting policies The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (‘IASB’) that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. New Accounting Standards and Interpretations not yet mandatory or early adopted International Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2023. The consolidated entity’s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity. Going concern The consolidated entity incurred a loss after income tax of $20,465,180 (2022: $25,014,055) was in a net current asset position of $3,207,572 (2022: $2,720,664) and had net cash outflows from operating activities of $15,156,157 (2022: $22,762,663) for the year ended 30 June 2023. As at 30 June 2023 the consolidated entity had cash in hand and at bank of $5,241,197 (2022: $7,361,112). The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the Company has not generated significant revenues nor does the company anticipate generating revenues in the near future. The ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. During the month of July 2023 through 7 August 2023, the Company raised total proceeds for the period of US$1,019,769 (A$1,540,918) using the ATM facility and continues to seek additional funding sources both in Australia and overseas. An ‘at-the-market’ of its ordinary shares, in the form of American Depositary Shares (ADSs), with each ADS representing The ATM allows the Company to raise capital dynamically in the market, with no discount, no warrant coverage, and modest banking fees, allowing it to fund operations with minimal dilution to existing shareholders. Accordingly the directors have prepared the financial statements on a going concern basis. There is substantial doubt on whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (‘IASB’). The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for contingent consideration which are carried at fair value. Critical accounting estimates The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3. Parent entity information In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 2 9 Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (‘company’ or ‘parent entity’) as at 30 June 2023 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the ‘consolidated entity’. Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. Where the consolidated entity loses control over a subsidiary, it derecognizes the assets including goodwill, liabilities and non-controlling Operating segments Operating segments are presented using the ‘management approach’, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. Foreign currency translation The financial statements are presented in Australian dollars. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation is disposed of. Exchange differences arising on a monetary item that forms part of a reporting entity’s net investment in a foreign operation shall be recognized initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. Financial Instruments Subsequent measurement of financial assets For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: • financial assets at amortised cost • financial assets at fair value through profit or loss (FVPL) Classifications are determined by both: • the entity’s business model for managing the financial asset • the contractual cash flow characteristics of the financial assets All income and expenses relating to financial assets that are recognized in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. Financial assets at amortised cost Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): • they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows; and • the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The consolidated entity’s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. Classification and measurement of financial liabilities The consolidated entity’s financial liabilities comprise trade and other payables. Financial liabilities, borrowings and contingent consideration for business combination and licensing agreement acquisitions are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the consolidated entity designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method, except for contingent consideration in a business combination, which is measured at fair value. All interest-related charges and, if applicable, changes in an instrument’s fair value that are reported in profit or loss are included within finance costs or finance income. Revenue from contracts with customers Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognized using a five step approach in accordance with IFRS 15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified within non-current The consolidated entity recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognizes either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. Licensing revenues, including milestone revenue Revenue from licensees of the consolidated entity’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. Finance Income Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. Grant Income Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions. Government grants relating to operating costs are recognized in the Statements of Comprehensive Income as grant income. A New South Wales Export Development Grant was received in the previous financial year. Other revenue Other revenue is recognized when it is received or when the right to receive payment is established. Income tax The income tax expense or benefit for the period is the tax payable on that period’s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. The carrying amount of recognized and unrecognized deferred tax assets are reviewed each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Kazia Therapeutics Limited (the ‘parent entity’) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the ‘separate taxpayer in the group’ allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. Interpretation 23 Uncertain tax positions Interpretation 23 clarified the application of the recognition and measurement criteria IAS 12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Management believes that historical tax losses are not expected to be available for offset against the deferred tax liability at 30 June 2023. Current and non-current Assets and liabilities are presented in the statement of financial position based on current and non-current An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Research and development Expenditure during the research phase of a project is recognized as an expense when incurred. Development costs are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. Intangible assets Separately acquired intangible assets are shown at historical cost. The cost of intangible assets acquired as part of a business combination is their fair value at the acquisition date. They have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. Licensing agreement for paxalisib The Licensing agreement asset was acquired as part of a business combination, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which Licensing agreement for EVT801 The Licensing agreement asset was acquired separately, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which Impairment of non-financial Non-financial Recoverable amount is the higher of an asset’s fair value less costs of disposal and value-in-use. value-in-use pre-tax Provisions Provisions are recognized when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognized as a finance cost. Employee benefits Short-term employee benefits Liabilities for wages and salaries, including non-monetary Other long-term employee benefits The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Share-based Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (‘ESOP’) and consultants as compensation for services performed. Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The value of the instruments is measured by reference to the fair value of the underlying instruments on grant date, as required by IFRS2 Share-Based Payments. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. The cumulative charge to profit or loss until settlement of the liability is calculated as follows: • during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. • from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. Finance costs Finance costs attributable to qualifying assets are capitalized as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. Fair value measurement When an asset or liability, financial or non-financial, Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. For recurring and non-recurring Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds. Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. Goods and Services Tax (‘GST’) and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Critical accounting judgements,

Critical accounting judgements, estimates and assumptions	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Critical accounting judgements, estimates and assumptions	Note 3. Critical accounting judgements, estimates and assumptions The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed as follows: Research and development expenses The Directors do not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalization of development costs. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting human clinical and pre-clinical Clinical trial expenses The timing of payment for work conducted under clinical trials often bears little relation to the timing of the work effort. Detailed estimates are made to determine the amount of work effort expended during a reporting period in order to determine the appropriate expense to be recognized, with the resulting prepayments or un-invoiced Share-based The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes option pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. Acquisition of intangible assets During the 2017 financial year, the consolidated entity acquired the rights to develop and commercialize paxalisib, as part of a business combination from Genentech. Significant judgement was required in determining that the transaction was a business combination and in relation to the identification and valuation of assets and liabilities acquired. The consolidated entity has applied judgement in determining the accounting treatment for the acquisition of the License agreement for EVT801. The License agreement has been determined to be a stand alone transaction, independent from any other agreements which have been or may be entered into with Evotec (France) SAS. Management has also made the decision to account for the cost of the asset conferred by the License agreement on the basis of the milestones that are probable of being payable, that is, those for which there is judged to be a probability of greater than Contingent consideration Contingent consideration relates to the intangible assets acquired, and the fair value of contingent consideration is dependent on the key assumptions used in accounting for the acquisition of those intangible assets. These assumptions include the probability of milestones occurring, and can also include the anticipated timing of settlement and discount rates used. In the case where contingent consideration is recognized on the basis that the liability is probable of occurring, judgement is used in determining which milestones are considered probable of being triggered and the timing thereof. Intangible assets available for use The consolidated entity has exercised judgement in determining that its intangible assets, being license agreements, have a finite life and are available for use once acquired. As the business model is to acquire such assets and then develop them to generate returns from future license transactions or other means, management have determined that the assets are available for use from the time that they are acquired. In each case the prima facie useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. Impairment of licensing agreements and other indefinite life intangible assets The consolidated entity assesses impairment of licensing agreements at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. Judgement is used to determine whether any indicators of impairment exist, and reference is made to the considerations included in IAS 36 Impairment of Assets in this assessment. If an impairment trigger is found to exist, the recoverable amount of the asset is determined.

Restatement of comparatives

Restatement of comparatives	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Restatement of comparatives	Note 4. Restatement of comparatives During the year ended 30 June 2023, the calculation of the EVT-801 EVT-801 30 June 2021 Increase/ 1 July 2021 30 June 2022 Increase/ 30 June 2022 A$’000 A$’000 A$’000 A$’000 A$’000 A$’000 Consolidated statement of financial position Intangibles - licensing agreement 27,265 (1,044 ) 26,221 27,266 (1,045 ) 26,221 Less Accumulated amortisation (5,263 ) 50 (5,213 ) (7,216 ) 134 (7,082 ) 22,002 (994 ) 21,008 20,050 (911 ) 19,139 Current contingent consideration (3,164 ) 2,373 (791 ) (759 ) — (759 ) Non-Current (8,926 ) (1,377 ) (10,303 ) (8,756 ) 547 (8,209 ) (12,091 ) 997 (11,094 ) (9,515 ) 547 (8,968 ) Net Assets 37,851 2 37,853 18,638 (364 ) 18,274 Accumulated losses (44,205 ) 2 (44,203 ) (68,253 ) (364 ) (68,617 ) Total equity 37,851 2 37,853 18,638 (364 ) 18,274 30 June 2022 Increase/ 30 June 2022 30 June 2021 Increase/ 30 June 2021 Consolidated statement of profit and loss Research and development expense (Amortisation) (20,252 ) 83 (20,169 ) (14,541 ) (14,541 ) General and administrative expense (foreign exchange impact) (4,511 ) (450 ) (4,961 ) (7,022 ) 2 (7,020 ) Loss on revaluation of contingent consideration (152 ) — (152 ) (2,570 ) (2,570 ) Commercialisation expense (127 ) — (127 ) Loss before tax (25,016 ) (366 ) (25,382 ) (8,906 ) 2 (8,904 ) Income tax benefit 368 — 368 484 484 Loss after tax (24,648 ) (366 ) (25,014 ) (8,422 ) 2 (8,420 ) Impact on basic and diluted earnings per share increase/ (decrease) in earning per share Basic loss for the year attributable to equity holders (18.61 ) (0.27 ) (18.88 ) (7.16 ) (7.16 ) Diluted loss for the year attributable to equity holders (18.61 ) (0.27 ) (18.88 ) (7.16 ) (7.16 )

Reclassification of comparative

Reclassification of comparatives	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Reclassification of comparatives	Note 5. Reclassification of comparatives During the preparation of the financial statements for the current year, a reclassification between borrowings and other assets was performed to better reflect the insurance funding premium utilized by the Company, a reclassification of non-current 30 June 2022 Reclassification 30 June 2022 Other assets 156 1,841 1,997 Borrowings — (1,841 ) (1,841 ) Current employee benefits 166 203 369 Non-current 319 (202 ) 117 Loss on remeasurement of contingent consideration 153 153 —  General and administrative expense (4,961 ) (153 ) (5,114 )

Revenue

Revenue	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Revenue	Note 6. Revenue 2023 A$’000 2022 A$’000 2021 A$’000 Licensing revenue —  —  15,183 Disaggregation of revenue The disaggregation of revenue from contracts with customers is as follows: 2023 A$’000 2022 A$’000 2021 A$’000 Geographical regions China —  —  10,006 Sweden —  —  5,177 —  —  15,183 Timing of revenue recognition Licensing revenue at a point in time —  —  15,183 During fiscal year 2021, the company recognized a total of US$11 million in accordance with the terms of the company’s license agreements with Oasmia Pharmaceutical AB and Simcere Pharmaceutical Group LTD. The terms of the license agreements are described in the following paragraphs. License Agreement with Oasmia Pharmaceutical AB In March 2021, the company entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical stage drug candidate for the treatment of ovarian cancer. During fiscal 2021, Oasmia made an upfront payment of US$4 million with contingent milestones of up to US$42 million and double-digit royalties on commercial sales. License Agreement with Simcere Pharmaceutical Group Ltd. In March 2021, the company entered into a licensing agreement with Simcere Pharmaceutical Group LTD. to develop and commercialize the company’s investigational drug candidate, paxalisib, in Greater China. Under the terms of the agreement, Simcere assumed responsibility for the development, registration and commercialization of paxalisib in Greater China (a territory that includes Mainland China, Hong Kong, Macau and Taiwan). The company received an upfront payment of US$ million comprising US$ million in cash and a US$ million equity investment, priced at a % premium to recent trading. The company will also receive contingent milestone payments of up to US$ million for glioblastoma, with further milestones payable for indications beyond glioblastoma. Simcere will additionally pay mid-teen percentage royalties on commercial sales. During fiscal year 2023, the company did not recognise revenue from either license agreements described in the above paragraphs in accordance with the terms of the agreements and revenue recognition policy in accordance with note 2.

Operating segments

Operating segments	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Operating segments	Note 7. Operating segments Identification of reportable operating segments The consolidated entity’s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (‘CODM’)) in assessing performance and in determining the allocation of resources. The The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position.

Other income

Other income	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Other income	Note 8. Other income 2023 A$’000 2022 A$’000 2021 A$’000 Payroll tax rebate — — 2 Subsidies and grants — 10 — Bad debt recovery — 15 Other sundry income 1 1 25 2

Expenses

Expenses	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Expenses	Note 9. Expenses 2023 A$’000 2022 A$’000 2021 Loss before income tax includes the following specific Research and development EVT-801 program costs 5,060 2,520 1,073 Cantrixil program costs 5 12 429 Paxalisib program costs 5,618 13,713 11,404 Scientific Advisory Board costs 31 — — Employee benefits expense - salaries & wages and staff benefits 2,250 1,665 336 - superannuation 29 25 26 - share based payments 702 365 8 Total research & development (excluding amortisation) 13,695 18,300 13,276 Amortisation Paxalisib licensing agreement 1,084 1,084 1,084 Evotech licensing agreement 785 785 181 Total amortisation 1,869 1,869 1,265 Total research & development 15,564 20,169 14,541 Net foreign exchange loss Net foreign exchange loss 46 (2,154 ) 409 Rental expense relating to operating leases Minimum lease payments 152 73 93 Superannuation expense Defined contribution superannuation expense 131 138 138 Employee benefits expense G&A - salaries & wages and staff benefits 1,467 1,674 1,011 - superannuation 102 129 112 - share based payments 457 1,310 552 Total employee benefits expense G&A 2,026 3,113 1,675 Other Expenses Chinese With-Holding — — 931 Chinese Value Added Tax incurred on license transaction — — 538 — — 1,469

Income tax benefit_expense

Income tax benefit/expense	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Income tax benefit/expense	Note 10 2022 2021 2023 restated restated A$’000 A$’000 A$’000 Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (20,736 ) (25,382 ) (8,904 ) Tax at the statutory tax rate of 25% (2022 25% 202 1 (5,184 ) (6,345 ) (2,316 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: Research and Development claim — — — Amortisation of intangibles 467 467 348 Employee option plan 289 419 175 Gain/loss on revaluation of contingent consideration (847 ) 38 707 (5,275 ) (5,421 ) (1,086 ) Adjustment recognized for prior periods — 16 — Adjustment to deferred tax balances as a result of change in statutory tax rate — (113 ) (186 ) Tax losses and timing differences not recognized 5,004 5,150 788 Income tax benefit (271 ) (368 ) (484 ) 2023 2022 2021 Tax losses not recognized Unused tax losses for which no deferred tax asset has been recognized-Australia 120,412 96,519 70,896 Potential tax benefit 25.0% (202 2 1 30,103 24,130 17,724 Unused tax losses for which no deferred tax asset has been recognized US 4,305 2,380 2,038 Potential tax benefit at statutory tax rates 21%-US 904 500 428

Current assets - cash and cash

Current assets - cash and cash equivalents	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Current assets - cash and cash equivalents	Note 1 1 2023 2022 A$’000 A$’000 Cash at bank and on hand 5,241 7,361 5,241 7,361

Trade and other receivables

Trade and other receivables	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Trade and other receivables	Note 1 2 2023 2022 A$’000 A$’000 Current assets Trade receivables 1 — GBM Agile deposit 3,753 — BAS receivables 104 51 Deposits held 41 40 3,899 91

Trade and other receivables - n

Trade and other receivables - non-current	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Trade and other receivables - non-current	Note 1 3 non-current 2023 2022 A$’000 A$’000 Non-current GBM Agile deposit — 7,258 Corporate credit card deposit 43 43 43 7,301 The GBM Agile deposit was advanced to GCAR at the start of the GBM Agile trial, and is refundable if not utilized against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial. Completion of the final analysis is expected in 2H CY2023. The deposit was moved to current for this reporting period.

Other assets

Other assets	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Current assets - other	Note 1 4 Current assets 2022 2023 Reclassified A$’000 A$’000 Prepayments 1,632 1,997 This contains the prepayment of invoices in relation to the annual insurance renewal program. An offsetting borrowing for the funding of this prepayment in included in Borrowings - See Note 17 Borrowings. Prepayment of annual insurance program invoices is included in Prepayments. An offsetting amount relating to the funding of insurance invoices is contained in Borrowings - See Note 17.

Intangibles

Intangibles	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Intangibles	Note 1 5 Non-current Consolidated 2022 2023 A$’000 restated A$’000 Licensing agreement - Paxalisib 16,408 16,408 Less: Accumulated amortisation (7,251 ) (6,166 ) 9,157 10,242 Licensing agreement - EVT-801 9,813 9,813 Less: Accumulated amortisation (1,701 ) (916 ) 8,112 8,897 17,269 19,139 Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: EVT801 licensing agreement A$’000 Paxalisib licensing agreement A$’000 Total A$’000 Balance at 1 July 2021 as restated 9,682 11,326 21,008 Amortisation expense (785 ) (1,084 ) (1,869 ) Balance at 30 June 2022 restated 8,897 10,242 19,139 Amortisation expense (785 ) (1,085 ) (1,870 ) Balance at 30 June 2023 8,112 9,157 17,269

Trade and other payables

Trade and other payables	12 Months Ended
	Jun. 30, 2023
1 year or less [member]
Statement [line items]
Trade and other payables	Note 1 6 2023 2022 A$’000 A$’000 Trade payables 857 1,524 Accrued payables 3,472 2,235 4,329 3,759 Refer to note 24 for further information on financial instruments.

Borrowings

Borrowings	12 Months Ended
	Jun. 30, 2023
Borrowings [abstract]
Borrowings	Note 1 7 Current liabilities 2023 2022 Reclassified A$’000 A$’000 Insurance premium funding 1,796 1,841 This is borrowing in relation to the annual insurance renewal program. An offsetting prepayment of insurance invoices in included in Prepaymens - See Note 14 Other Assets. Borrowings in relation to funding of annual insurance program renewal. An offsetting amount relating to the prepayment of insurance invoices is contained in Prepayments - See Note 14.

Employee benefits

Employee benefits	12 Months Ended
	Jun. 30, 2023
1 year or less [member]
Statement [line items]
Employee benefits	Note 1 8 2023 2022 reclassified A$’000 Current Liabilities Employee benefits 201 — Annual leave 489 369 690 369 Non-Current Long service leave 59 117 749 486

Contingent consideration

Contingent consideration	12 Months Ended
	Jun. 30, 2023
Statement [line items]
Contingent consideration	Note 1 9 2023 2022 Current Liabilities Contingent consideration – Paxalisib 750 —  Contingent consideration – EVT801 —  759 750 759 Non-current Contingent consideration - paxalisib 654 1,168 Contingent consideration – EVT801 5,467 7,041 6,121 8,209 6,871 8,968 Reconciliations Reconciliation of the balance at the beginning and end of the reporting period is set out below: Consolidated 2022 2023 restated $ $ Contingent consideration at start of period (current and non-current) 8,968 11,094 Payment of EVT801 milestone — (2,364 ) Interest on unwinding of discount 594 567 Effect of exchange rates on contingent consideration 697 (329 ) Gain on remeasurement of contingent consideration (3,388 ) — 6,871 8,968 Contingent consideration - paxalisib During the 2017 financial year, the consolidated entity acquired the rights to develop and commercialize paxalisib, as part of a business combination. The acquisition contained four development contingent milestone payments, the first two milestone payment settlements being Kazia shares, and the third and fourth development milestone payment settlements either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the Each milestone payment is probability weighted for valuation purposes. Milestone 2 is now a current liability and is no longer being discounted. Milestone 5 is a revenue based milestone contingent on net sales and is discounted to present value, using a discount rate of 20% (previously 15%) per annum. The discount rate was considered at 30 June 2023 and revised to reflect a rate within a more reasonable market range. Accordingly, the discount rate applied to future expected cash flows has been revised upwards. Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance, and are not considered as part of the consideration in relation to the Genentech agreement. Contingent consideration - EVT801 The acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being booked as a current or non-current

Deferred tax

Deferred tax	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Deferred tax	Note 20 2023 2022 A$’000 A$’000 Non-current Deferred tax liability associated with Licensing Agreement 2,289 2,560 Company management has completed an analysis of the availability of historical tax losses to offset the deferred tax liability. Accordingly, the company concludes that the historical tax losses are not expected to be available for offset against the deferred tax liability.

Equity - contributed equity

Equity - contributed equity	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Equity - contributed equity	Note 2 1 Consolidated 2023 2022 2023 2022 Shares Shares $ $ Ordinary shares - fully paid 228,029,114 138,755,376 97,452,246 84,480,249 Movements in ordinary share capital Details Date Shares Issue price $ Balance 1 July 2021 132,012,209 80,290,062 Issued on conversion of options 15 December 2021 25,000 $ 0.6680 16,700 Conversion of Triaxial Convertible Note 5 May 2022 1,855,357 $ 0.2500 464,000 ATM issue of shares No. 1 24 May 2022 10,000 $ 0.8260 8,256 ATM issue of shares No. 2 2 June 2022 10,000 $ 0.8020 8,025 ATM issue of shares No. 3 6 June 2022 88,710 $ 0.8370 74,258 ATM issue of shares No. 4 9 June 2022 603,500 $ 0.8400 507,035 ATM issue of shares No. 5 14 June 2022 75,940 $ 0.8240 62,583 ATM issue of shares No. 6 15 June 2022 2,000 $ 0.8300 1,661 ATM issue of shares No. 7 20 June 2022 4,072,660 $ 0.8690 3,540,403 Less: share issue transaction costs — $ 0.0000 (492,735 ) Balance 30 June 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Shares issued to Scientific Advisory Board 14 September 2022 60,000 $ 0.2100 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 ATM issue of shares No. 18 11 January 2023 20,000 $ 0.1380 2,761 Professional and sophisticated investors placement – 1st tranche 16 January 2023 25,387,018 $ 0.1100 2,792,572 Professional and sophisticated investors placement – 2nd tranche 2 15,522,075 $ 0.1100 1,707,428 Share Placement Plan 3 March 2023 23,691,045 $ 0.1100 2,606,000 Less: share issue transaction costs — $ 0.0000 (400,750 ) Balance 228,029,114 97,452,246 Ordinary shares Ordinary On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Share buy-back There is no current on-market buy-back. Capital risk management The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can Capital is regarded as total equity, as recognized in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. The capital risk management policy remains unchanged from the prior year.

Equity - reserves

Equity - reserves	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Equity - reserves	Note 22. Equity - reserves 2023 2022 A$’000 A$’000 Foreign currency reserve (742 ) (852 ) Share-based payments reserve 4,423 3,264 3,681 2,412 Foreign currency translation reserve The reserve is used to recognise exchange differences arising from translation of the financial statements of foreign operations to Australian dollars. Share-based The reserve is used to recognise the value of equity benefits provided to employees and executive directors as part of their remuneration, and other parties as part of their compensation for services.

Equity - dividends

Equity - dividends	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Equity - dividends	Note 23. Equity - dividends Dividends There were no dividends paid, recommended or declared during the current or previous financial year.

Financial instruments

Financial instruments	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Financial instruments	Note 24. Financial instruments Financial risk management objectives The consolidated entity’s activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The consolidated entity uses different methods to measure and manage the different types of risks to which it is exposed. These methods include monitoring the levels of exposure to interest rates and foreign exchange, ageing analysis and monitoring of specific credit allowances to manage credit risk, and, rolling cash flow forecasts to manage liquidity risk. Market risk Foreign currency risk The consolidated entity operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollars (‘USD’). Foreign exchange risk arises from future transactions and recognized assets and liabilities denominated in a currency that is not the entity’s functional currency and net investments in foreign operations. As of 30 June 2023 and 2022, the consolidated entity did not hold derivative financial instruments in managing its foreign currency, however, the consolidated entity may from time to time enter into hedging arrangements where circumstances are deemed appropriate. The consolidated entity used natural hedging to reduce the foreign currency risk, which involved processing USD payments from cash held in USD. Foreign subsidiaries with a functional currency of Australian Dollars (‘AUD’) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. The carrying amount of the consolidated entity’s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: Assets Liabilities 2023 A$’000 2022 restated A$’000 2023 A$’000 2022 A$’000 US dollars 2,326 7,276 1,135 3,071 Euros — — 2,710 205 Singapore dollars — — 1 — 2,326 7,276 3,846 3,276 The consolidated entity had net assets denominated in foreign currencies of A$2,232,754 as at 30 June 2023 (2022: net assets A$3,999,645). If all currencies had strengthened and weakened AUD strengthened AUD weakened Consolidated - 2023 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (494 ) (494 ) (10 %) 494 494 Euros 10 % 271 271 (10 %) (271 ) (271 ) (223 ) (223 ) 223 223 AUD strengthened AUD weakened Consolidated – 2022 (restated) % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (420 ) (420 ) (10 %) 420 420 Euros 10 % 20 20 (10 %) (20 ) (20 ) (400 ) (400 ) 400 400 Price risk The consolidated entity is not exposed to any significant price risk. Interest rate risk The consolidated entity’s exposure to market interest rates relate primarily to the investments of cash balances. The consolidated entity has cash reserves held primarily in Australian dollars and United States dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. As at the reporting date, the consolidated entity had the following variable interest rate balances: 2023 2022 Weighted average interest rate % Balance A$’000 Weighted average interest rate % Balance A$’000 Cash at bank and in hand 0.40 5,241 —  7,361 Net exposure to cash flow interest rate risk 5,241 7,361 The consolidated entity has cash and cash equivalents totalling $5,241,197 (2022: $7,361,112). An official increase/decrease in interest rates of 100 basis points 100 basis points Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The entity is not exposed to significant credit risk on receivables. The consolidated entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the consolidated entity based on recent sales experience, historical collection rates and forward-looking information that is available. The consolidated entity places its cash deposits with high credit quality financial institutions and by policy, limits the amount of credit exposure to any single counter-party. The consolidated entity is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk, and reinvestment risk. The consolidated entity mitigates default risk by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year. There are no significant concentrations of credit risk within the consolidated entity. The credit risk on liquid funds is limited as the counter parties are banks with high credit ratings. Credit risk is managed by limiting the amount of credit exposure to any single counter-party for cash deposits. Liquidity risk The consolidated entity manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities. In particular, contingent consideration may be satisfied either by payment of cash or by issue of shares, at the discretion of the entity. Remaining contractual maturities The following tables detail the consolidated entity’s remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position. 2023 Weighted average % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining Non-derivatives Trade payables — 857 — — — 857 Accrued payables — 3,472 — — — 3,472 Contingent consideration — 750 4,303 3,099 — 8,152 Total non-derivatives 5,079 4,303 3,099 — 12,481 2022 restated Weighted average 1 year or less Between Between Over Remaining Non-derivatives Trade payables — 1,524 — — — 1,524 Accrued payables — 2,236 — — — 2,236 Contingent consideration — 759 8,338 795 — 9,892 Total non-derivatives 4,519 8,338 795 — 13,652 The cash flows in the maturi t

Fair value measurement

Fair value measurement	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Fair value measurement	Note 2 5 Fair value hierarchy The following tables detail the consolidated entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3: Unobservable inputs for the asset or liability Consolidated - 2023 Level 1 A$’000 Level 2 A$’000 Level 3 A$’000 Total A$’000 Liabilities Contingent Consideration — — 1,404 1,404 Total liabilities — — 1,404 1,404 Consolidated - 2022 Liabilities Contingent Consideration — — 1,168 1,168 Total liabilities — — 1,168 1,168 There were no transfers between levels during the financial year. The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the license agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting. The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors’ assessment of achieving contracted milestones as disclosed in Note 1 9 Level 3 assets and liabilities Movements in level 3 assets and liabilities during the current and previous financial year are set out below: Level 3 A$’000 Total A$’000 Consolidated Balance at 1 July 2021 1,015 1,015 Losses recognized in profit or loss 153 153 Balance at 30 June 2022 1,168 1,168 Losses recognized in profit or loss 236 236 Balance at 30 June 2023 1,404 1,404

Key management personnel disclo

Key management personnel disclosures	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Key management personnel disclosures	Note 2 6 Compensation The aggregate compensation made to directors and other members of key management personnel (‘KMP’) of the consolidated entity is set out below: 2023 A$’000 2022 A$’000 2021 A$’000 Short-term employee benefits 3,148 2,589 1,574 Post-employment benefits 150 116 112 Share-based payments 1,046 1,560 617 4,344 4,265 2,303 Please refer to Note 28 for other transactions with key management personnel and their related parties.

Remuneration of auditors

Remuneration of auditors	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Remuneration of auditors	Note 27. Remuneration of auditors During the financial year the following fees were paid or payable for services provided by BDO Audit Pty Ltd, the auditor of the Company: 2023 2022 2021 Audit services – BDO Audit Pty Ltd Audit or review of the financial statements 292 — — Other services BDO Audit Pty Ltd Comfort letter – ATM 18 — — 310 — — Audit services – Grant Thornton Audit Pty Ltd Audit or review of the financial statements — 155 151 Other services - Grant Thornton Audit Pty Ltd Comfort letter – ATM — 26 — — 181 151

Related party transactions

Related party transactions	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Related party transactions	Note 28. Related party transactions Parent entity Kazia Therapeutics Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 30. Key management personnel Disclosures relating to key management personnel are set out in note 26. Transactions with related parties There were no other transactions with KMP and their related parties. Receivable from and payable to related parties There were no trade receivables from or trade payables to related parties at the current and previous reporting date. Loans to/from related parties There were no loans to or from related parties at the current and previous reporting date. Terms and conditions All transactions were made on normal commercial terms and conditions and at market rates.

Parent entity information

Parent entity information	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Parent entity information	Note 29. Parent entity information Set out below is the supplementary information about the parent entity. Parent 2023 2022 Statement of profit or loss and other comprehensive income Loss after income tax (20,863 ) (24,241 ) Total comprehensive income (20,863 ) (24,241 ) 2023 2022 Statement of financial position Total current assets 4,645 7,736 Total assets 21,915 26,875 Total current liabilities 7,003 2,931 Total liabilities 15,472 13,701 Equity Contributed equity 97,452 84,480 Reserves 4,423 3,264 Accumulated losses (95,432 ) (74,570 ) Total equity 6,443 13,174 Reserves comprise Share Based Payments Reserve. Contingent liabilities The parent entity contingent liabilities as at 30 June 2023 and 30 June 2022 are as set out in note 19. Capital commitments - Property, plant and equipment The parent entity had no capital commitments for property, plant and equipment at as 30 June 2023 and 30 June 2022. Significant accounting policies The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following: • Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. • Dividends received from subsidiaries are recognized as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Interests in subsidiaries

Interests in subsidiaries	12 Months Ended
	Jun. 30, 2023
Investments accounted for using equity method [abstract]
Interests in subsidiaries	Note 30 The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2: Ownership interest Name Principal place of business / Country of incorporation 2023 % 2022 % Kazia Laboratories Pty Ltd Australia 100.00 % 100.00 % Kazia Research Pty Ltd Australia 100.00 % 100.00 % Kazia Therapeutics Inc. United States of America 100.00 % 100.00 % Glioblast Pty Ltd Australia 100.00 % 100.00 % *Kazia Therapeutics (Hong Kong) Limited Hong Kong — 100.00 % *Kazia Therapeutics (Hong Kong) Limited was formally deregistered and dissolved on 10 March 2023.

Reconciliation of loss after in

Reconciliation of loss after income tax to net cash used in operating activities	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Reconciliation of loss after income tax to net cash used in operating activities	Note 31. Reconciliation of loss after income tax to net cash used in operating activities 2023 2022 restated 2021 restated A$’000 A$’000 A$’000 Loss after income tax expense from continuing operations (20,465 ) (25,014 ) (8,420 ) Adjustments for: Depreciation & amortisation 1,869 1,869 1,265 Net fair value loss on financial assets — — — Share based payments 1,159 1,675 637 Foreign exchange differences 46 (2,154 ) 428 (Gain)/loss on remeasurement of contingent consideration (2,097 ) — 2,570 Change in operating assets & liabilities: (19,488 ) (23,624 ) (3,520 ) Decrease/(increase) in trade and other receivables 3,450 (7 ) (5,027 ) Decrease/(increase) in prepayments 365 (277 ) (1,182 ) Decrease/(increase) in trade and other payables 569 (528 ) 1,010 Decrease in deferred tax liability (271 ) (368 ) (484 ) Increase in other provisions 264 201 92 (Decrease)/increase in borrowings (45 ) 1,841 — Net cash used in operating activities (15,156 ) (22,762 ) (9,111 )

Earnings per share

Earnings per share	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Earnings per share	Note 3 2 2023 A$’000 2022 restated 2021 restated A$’000 Earnings per share for loss from continuing operations Loss after income tax attributable to the owners of Kazia Therapeutics Limited (20,465 ) (25,014 ) (8,420 ) Loss after income tax attributable to the owners of Kazia Therapeutics Limited (20,465 ) (25,014 ) (8,420 ) Number Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 184,284,350 132,467,686 117,674,543 Weighted average number of ordinary shares used in calculating diluted earnings per share 184,284,350 132,467,686 117,674,543 Cents Cents Cents Basic earnings per share (11.23 ) (18.88 ) (7.16 ) Diluted earnings per share (11.23 ) (18.88 ) (7.16 ) The number of unissued shares under option that have been excluded from the diluted EPS are (2023) (2022) and

Share-based payments

Share-based payments	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Share-based payments	Note 3 3 Share-based All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $1,159,125 (30 June 2022: $1,674,581) was recognized. Number of 2023 Weighted Number of Weighted Outstanding at the beginning of the financial year 8,655,500 $ 1.2826 4,219,000 $ 0.8911 Granted 7,930,000 $ 0.1785 4,800,000 $ 1.6115 Forfeited (1,550,000 ) $ 1.8977 — $ 0.0000 Exercised — $ 0.0000 (25,000 ) $ 0.6700 Expired (255,500 ) $ 1.8977 (338,500 ) $ 1.1123 Outstanding at the end of the financial year 14,780,000 $ 0.6292 8,655,500 $ 1.2826 Exercisable at the end of the financial year 6,483,333 $ 0.9572 3,180,500 $ 0.8770 2023 Tranche Grant date Expiry date Exercise Balance at Granted Exercised Expired / Balance at 1 07/08/2017 07/08/2022 $ 0.6700 15,500 — — (15,500 ) — 2 05/02/2018 05/02/2023 $ 0.7802 240,000 — — (240,000 ) — 3 13/11/2019 04/01/2024 $ 0.4925 1,200,000 — — — 1,200,000 4 13/01/2020 13/01/2025 $ 0.8812 200,000 — — (12,500 ) 187,500 5 09/11/2020 09/11/2024 $ 1.1320 1,200,000 — — — 1,200,000 6 09/11/2020 13/01/2025 $ 0.8812 800,000 — — (200,000 ) 600,000 7 04/01/2021 04/01/2025 $ 1.6900 200,000 — — (12,500 ) 187,500 8 09/09/2021 26/06/2026 $ 1.3650 100,000 — — — 100,000 9 16/11/2021 16/11/2025 $ 1.6900 1,000,000 — — (250,000 ) 750,000 10 16/11/2021 16/11/2025 $ 2.2400 1,500,000 — — (1,000,000 ) 500,000 11 16/11/2021 16/11/2026 $ 1.5600 800,000 — — — 800,000 12 01/02/2022 01/02/2027 $ 0.9400 800,000 — — — 800,000 13 01/02/2022 01/02/2027 $ 0.9400 500,000 — — (75,000 ) 425,000 14 24/05/2022 24/05/2027 $ 0.7800 100,000 — — — 100,000 15 03/03/2023 03/03/2027 $ 0.1500 — 3,930,000 — — 3,930,000 16 03/05/2023 03/05/2027 $ 0.1870 — 4,000,000 — — 4,000,000 8,655,500 7,930,000 — (1,805,500 ) 14,780,000 Weighted average exercise price $ 1.2826 $ 0.1785 $ 0.0000 $ 1.8977 $ 0.6292 At the end of the period the following outstanding options were vested and exercisable: - Options in tranches - Options in tranches - Options in tranches - Options in tranche - Options in tranches - Options in tranches - Options in tranche 15 were unvested - Options in tranche 16 were 33% vested The 2022 Tranche Grant date Expiry date Exercise Balance at Granted Exercised Expired / Balance at 1 05/09/2016 05/09/2021 $ 1.6300 50,000 — — (50,000 ) — 2 12/10/2016 17/10/2021 $ 1.5600 62,000 — — (62,000 ) — 3 31/10/2016 01/11/2021 $ 1.3800 12,500 — — (12,500 ) — 4 21/11/2016 23/11/2021 $ 1.3800 50,000 — — (50,000 ) — 5 07/08/2017 07/08/2022 $ 0.6700 87,000 — (25,000 ) (46,500 ) 15,500 6 05/02/2018 05/02/2023 $ 0.7800 320,000 — — (80,000 ) 240,000 7 04/01/2019 04/01/2024 $ 0.4925 37,500 — — (37,500 ) — 8 13/11/2019 13/11/2023 $ 0.4925 1,200,000 — — — 1,200,000 9 13/01/2020 13/01/2025 $ 0.8812 200,000 — — — 200,000 10 09/11/2020 09/11/2024 $ 1.1320 1,200,000 — — — 1,200,000 11 09/11/2020 09/11/2024 $ 0.8812 800,000 — — — 800,000 12 04/01/2021 04/01/2026 $ 1.6900 200,000 — — 200,000 13 09/09/2021 26/06/2026 $ 1.3700 — 100,000 — — 100,000 14 16/11/2021 16/11/2025 $ 1.6900 — 1,000,000 — — 1,000,000 15 16/11/2021 16/11/2025 $ 2.2400 — 1,500,000 — — 1,500,000 16 16/11/2021 16/11/2025 $ 1.5600 — 800,000 — — 800,000 17 01/02/2022 01/02/2027 $ 0.9400 — 800,000 — — 800,000 18 01/02/2022 01/02/2027 $ 0.9400 — 500,000 — — 500,000 19 24/05/2022 24/05/2027 $ 0.7800 — 100,000 — — 100,000 4,219,000 4,800,000 (25,000 ) (338,500 ) 8,655,500 Weighted average exercise price $ 0.8911 $ 1.6110 $ 0.6700 $ 1.1123 $ 1.2826 At the end of the period the following outstanding options were - Options in tranche 1- - Options in tranches 1 - 8 were vested and exercisable, apart from those in the above table which have expired - Options in tranche 9 -10 - Options in tranche 11 were vested and exercisable to 75% - Options in tranche 12-14 - Options in tranche 15-19 The weighted average remaining contractual life of options outstanding at 30 June 2022 is 3.048 years. Employee share options During the year ended 30 June 2023, 7,930,000 options have been issued to directors and employees by the consolidated entity pursuant to the Company’s Employee Share Option Plan. • Tranches 12 & 13 vests 25% 6 months from issue date and then in 3 amounts at 6 monthly intervals from the date of issue. • Tranches 14 vests 33% immediately then in two equal amounts annually from the date of grant. • Tranches 15 vests 6 months from issue date then in two equal amounts annually from the date of grant. • Tranches 16 vests 33% immediately then in two equal amounts annually from the date of grant. Vesting Conditions for an option to be exercised: • The option must have vested; • Option holder must have provided the Company with an Exercise Notice and have paid the Exercise Price for the option; • The Exercise Notice must be for the exercise of at least the Minimum Number of Options; and • The Exercise Notice must have been provided to the Company and Exercise Price paid before the expiry of 4 years from the date the Option is issued. Options Valuation In order to obtain a fair valuation of these options, the following assumptions have been made: The Black Scholes option valuation methodology has been used with the expectation that the majority of these options would be exercised towards the end of the option term. Inputs into the Black Scholes model includes the share price at grant date, exercise price, volatility, and the risk free rate of a five year Australian Government Bond on grant date. Risk-free For all tranches, the risk-free rate of a five-year Australian Government bond on grant date was used. Please refer to the table below for details. The abovementioned options have various vesting periods and exercising conditions. These options are unlisted as at 30 June 2023. No dividends are expected to be declared or paid by the consolidated entity during the terms of the options. The underlying expected volatility was determined by reference to historical data of the Company’s shares over a period of time. No special features inherent to the options granted were incorporated into measurement of fair value. Based on the above assumptions, the table below sets out the valuation for each tranche of options: Grant date Expiry date Share price at Grant Date Exercise Volatility (%) Dividend Risk free Rate (%) Fair value 13/11/2019 04/01/2024 $0.4100 $0.4925 74.50% — 1.95% $ 0.180 13/01/2020 13/01/2025 $0.6200 $0.8812 74.50% — 1.95% $ 0.340 09/11/2020 13/11/2024 $0.8900 $1.1320 90.00% — 0.10% $ 0.413 09/11/2020 13/01/2025 $0.8900 $0.8812 90.00% — 0.10% $ 0.503 04/01/2021 04/01/2025 $1.1850 $1.6900 90.00% — 0.19% $ 0.600 09/09/2021 21/06/2026 $1.4200 $1.3700 76.00% — 1.50% $ 0.880 16/11/2021 16/11/2025 $1.5700 $1.6900 76.00% — 1.50% $ 0.850 16/11/2021 16/11/2025 $1.5700 $2.2400 76.00% — 1.50% $ 0.750 16/11/2021 16/11/2026 $1.5700 $1.5600 76.00% — 1.50% $ 0.970 01/02/2022 01/02/2027 $0.9600 $0.9400 79.00% — 1.50% $ 0.590 24/05/2022 24/05/2027 $0.8000 $0.7800 44.00% — 2.95% $ 0.630 03/01/2023 03/03/2027 $0.1700 $0.1500 80.00% — 3.64% $ 0.10137 03/03/2023 03/03/2027 $0.1700 $0.1500 80.00% — 3.64% $ 0.10137 03/05/2023 03/05/2027 $0.1900 $0.1870 80.00% — 3.22% $ 0.11110

Subsequent events

Subsequent events	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Subsequent events	Note 34. Subsequent events Fast Track Designation from US FDA for paxalisib Paxalisib was awarded Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) for the treatment of solid tumour brain metastases harbouring PI3K pathway mutations in combination with radiation therapy. The FDA’s decision to grant FTD was based on promising clinical data from an interim analysis of an ongoing Phase 1 clinical trial in which patients with brain metastases from a primary tumour are receiving paxalisib in combination with radiotherapy (NCT04192981). These clinical data were presented at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, jointly organized by the Society for Neuro-Oncology (SNO) and the American Society for Clinical Oncology (ASCO), by Dr. Jonathan Yang, lead investigator in the clinical trial. All nine evaluable patients in the trial (100%) responded to the combination of paxalisib with radiotherapy. Published benchmarks suggest a typical response rate for radiotherapy alone to be around 20-40%. Fast Track Designation is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life threatening conditions. It provides Kazia with enhanced access to FDA, including opportunities for face-to-face At-The-Market (ATM) Issuances During the month of July 2023 through 7 August 2023, the Company raised total proceeds for the period of US$1,019,769 (A$1,540,918). increasing the total shares outstanding to 236,349,374. Shares issued under the ATM are issued at the spot market price, with no discount, no accompanying warrants or options, and with banking fees approximately half of those associated with more traditional financing methods. Resignation of Chairman Kazia announced that Dr John Friend joined the Kazia Board as Managing Director on 1 August 2023. Kazia announced the resignation of Mr. Iain Ross as Chairman and non-executive No other matter or circumstance has arisen since 30 June 202 3 Kazia announces voluntary delisting from ASX On 11 October 2023 Kazia announced that it submitted a formal application to the ASX to be removed from the official list of the ASX (Official List) in accordance with ASX Listing Rule 17.11 (Delist or the Delisting). This formal request followed the receipt of in-principle advice from the ASX in relation to the proposed Delisting, subject to the satisfaction of certain conditions. Kazia’s Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweighed any benefits of a continued ASX listing. Following the Delisting, the Company will maintain its listing on the Nasdaq and the fully paid ordinary shares in the Company (Shares) will no longer be quoted on the ASX. ASX’s in-principle decision to approve the Delisting is subject to the Company’s compliance with the following conditions imposed by ASX under Listing Rule 17.11 and Guidance Note 33: (a) The Company sends written or electronic communications to all shareholders whose Shares are held on the Company’s Australian principal share register, in form and substance satisfactory to ASX (Notice), setting out: (i) the nominated time and date at which the entity will be removed from the ASX and that: (A) if they wish to sell their Shares on ASX, they will need to do so before then; and (B) if they don’t, thereafter they will only be able to sell the underlying securities on-market on Nasdaq in the form of ADSs; and (ii) generally what they need to do if they wish to sell their securities on Nasdaq. (b) The removal shall not take place any earlier than one month after the date the information in the Notice has been sent to shareholders. (c) The Company releases the full terms of this decision to the market upon making a formal application to ASX to remove the Company from the official list of ASX. Importantly, Kazia shareholder approval is not required for the Delisting.

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
New or amended Accounting Standards and Interpretations adopted	New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (‘IASB’) that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
New Accounting Standards and Interpretations not yet mandatory or early adopted	New Accounting Standards and Interpretations not yet mandatory or early adopted International Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2023. The consolidated entity’s assessment of the impact of these new or amended Accounting Standards and Interpretations is that none are deemed to have a material impact on the entity.
Going concern	Going concern The consolidated entity incurred a loss after income tax of $20,465,180 (2022: $25,014,055) was in a net current asset position of $3,207,572 (2022: $2,720,664) and had net cash outflows from operating activities of $15,156,157 (2022: $22,762,663) for the year ended 30 June 2023. As at 30 June 2023 the consolidated entity had cash in hand and at bank of $5,241,197 (2022: $7,361,112). The financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the Company has not generated significant revenues nor does the company anticipate generating revenues in the near future. The ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. During the month of July 2023 through 7 August 2023, the Company raised total proceeds for the period of US$1,019,769 (A$1,540,918) using the ATM facility and continues to seek additional funding sources both in Australia and overseas. An ‘at-the-market’ of its ordinary shares, in the form of American Depositary Shares (ADSs), with each ADS representing The ATM allows the Company to raise capital dynamically in the market, with no discount, no warrant coverage, and modest banking fees, allowing it to fund operations with minimal dilution to existing shareholders. Accordingly the directors have prepared the financial statements on a going concern basis. There is substantial doubt on whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements.
Basis of preparation	Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board (‘IASB’). The financial statements have been prepared on an accruals basis and under the historical cost conventions, except for contingent consideration which are carried at fair value. Critical accounting estimates The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.
Parent entity information	Parent entity information In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 2 9
Principles of consolidation	Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited (‘company’ or ‘parent entity’) as at 30 June 2023 and the results of all subsidiaries for the year then ended. Kazia Therapeutics Limited and its subsidiaries together are referred to in these financial statements as the ‘consolidated entity’. Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. Where the consolidated entity loses control over a subsidiary, it derecognizes the assets including goodwill, liabilities and non-controlling
Operating segments	Operating segments Operating segments are presented using the ‘management approach’, where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors.
Foreign currency translation	Foreign currency translation The financial statements are presented in Australian dollars. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation is disposed of. Exchange differences arising on a monetary item that forms part of a reporting entity’s net investment in a foreign operation shall be recognized initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment.
Financial instruments	Financial Instruments Subsequent measurement of financial assets For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: • financial assets at amortised cost • financial assets at fair value through profit or loss (FVPL) Classifications are determined by both: • the entity’s business model for managing the financial asset • the contractual cash flow characteristics of the financial assets All income and expenses relating to financial assets that are recognized in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. Financial assets at amortised cost Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): • they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows; and • the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The consolidated entity’s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. Classification and measurement of financial liabilities The consolidated entity’s financial liabilities comprise trade and other payables. Financial liabilities, borrowings and contingent consideration for business combination and licensing agreement acquisitions are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the consolidated entity designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method, except for contingent consideration in a business combination, which is measured at fair value. All interest-related charges and, if applicable, changes in an instrument’s fair value that are reported in profit or loss are included within finance costs or finance income. Revenue from contracts with customers Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. Revenue is recognized using a five step approach in accordance with IFRS 15 Revenue from Contracts with Customers to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the consolidated entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified within non-current The consolidated entity recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the consolidated entity satisfies a performance obligation before it receives the consideration, the consolidated entity recognizes either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. Licensing revenues, including milestone revenue Revenue from licensees of the consolidated entity’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. Finance Income Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. Grant Income Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions. Government grants relating to operating costs are recognized in the Statements of Comprehensive Income as grant income. A New South Wales Export Development Grant was received in the previous financial year. Other revenue Other revenue is recognized when it is received or when the right to receive payment is established.
Income tax	Income tax The income tax expense or benefit for the period is the tax payable on that period’s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. The carrying amount of recognized and unrecognized deferred tax assets are reviewed each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Kazia Therapeutics Limited (the ‘parent entity’) and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the ‘separate taxpayer in the group’ allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. As the tax consolidation group continues to generate tax losses there has been no reason for the company to enter a tax funding agreement with members of the tax consolidation group. Interpretation 23 Uncertain tax positions Interpretation 23 clarified the application of the recognition and measurement criteria IAS 12 Income Taxes where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Management believes that historical tax losses are not expected to be available for offset against the deferred tax liability at 30 June 2023.
Current and non-current classification	Current and non-current Assets and liabilities are presented in the statement of financial position based on current and non-current An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
Research and development	Research and development Expenditure during the research phase of a project is recognized as an expense when incurred. Development costs are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.
Intangible assets	Intangible assets Separately acquired intangible assets are shown at historical cost. The cost of intangible assets acquired as part of a business combination is their fair value at the acquisition date. They have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period. Amortisation expense is included in research and development expenditure. Licensing agreement for paxalisib The Licensing agreement asset was acquired as part of a business combination, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which Licensing agreement for EVT801 The Licensing agreement asset was acquired separately, and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent, which
Impairment of non-financial assets	Impairment of non-financial Non-financial Recoverable amount is the higher of an asset’s fair value less costs of disposal and value-in-use. value-in-use pre-tax
Provisions	Provisions Provisions are recognized when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognized as a finance cost.
Employee benefits	Employee benefits Short-term employee benefits Liabilities for wages and salaries, including non-monetary Other long-term employee benefits The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.
Share-based payments	Share-based Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (‘ESOP’) and consultants as compensation for services performed. Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The value of the instruments is measured by reference to the fair value of the underlying instruments on grant date, as required by IFRS2 Share-Based Payments. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. The cumulative charge to profit or loss until settlement of the liability is calculated as follows: • during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. • from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date. Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.
Finance costs	Finance costs Finance costs attributable to qualifying assets are capitalized as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings.
Fair value measurement	Fair value measurement When an asset or liability, financial or non-financial, Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. For recurring and non-recurring
Issued capital	Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, including share based payments relating to the issue of shares are, shown in equity as a deduction, net of tax, from the proceeds.
Earnings per share	Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
Goods and Services Tax ('GST') and other similar taxes	Goods and Services Tax (‘GST’) and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Restatement of comparatives (Ta

Restatement of comparatives (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Schedule Of Material Restatement Of EVT 801 Asset	The error resulted in a material overstatement of the EVT-801 30 June 2021 Increase/ 1 July 2021 30 June 2022 Increase/ 30 June 2022 A$’000 A$’000 A$’000 A$’000 A$’000 A$’000 Consolidated statement of financial position Intangibles - licensing agreement 27,265 (1,044 ) 26,221 27,266 (1,045 ) 26,221 Less Accumulated amortisation (5,263 ) 50 (5,213 ) (7,216 ) 134 (7,082 ) 22,002 (994 ) 21,008 20,050 (911 ) 19,139 Current contingent consideration (3,164 ) 2,373 (791 ) (759 ) — (759 ) Non-Current (8,926 ) (1,377 ) (10,303 ) (8,756 ) 547 (8,209 ) (12,091 ) 997 (11,094 ) (9,515 ) 547 (8,968 ) Net Assets 37,851 2 37,853 18,638 (364 ) 18,274 Accumulated losses (44,205 ) 2 (44,203 ) (68,253 ) (364 ) (68,617 ) Total equity 37,851 2 37,853 18,638 (364 ) 18,274
Schedule Of Material Restatement Of Income Statement	30 June 2022 Increase/ 30 June 2022 30 June 2021 Increase/ 30 June 2021 Consolidated statement of profit and loss Research and development expense (Amortisation) (20,252 ) 83 (20,169 ) (14,541 ) (14,541 ) General and administrative expense (foreign exchange impact) (4,511 ) (450 ) (4,961 ) (7,022 ) 2 (7,020 ) Loss on revaluation of contingent consideration (152 ) — (152 ) (2,570 ) (2,570 ) Commercialisation expense (127 ) — (127 ) Loss before tax (25,016 ) (366 ) (25,382 ) (8,906 ) 2 (8,904 ) Income tax benefit 368 — 368 484 484 Loss after tax (24,648 ) (366 ) (25,014 ) (8,422 ) 2 (8,420 ) Impact on basic and diluted earnings per share increase/ (decrease) in earning per share Basic loss for the year attributable to equity holders (18.61 ) (0.27 ) (18.88 ) (7.16 ) (7.16 ) Diluted loss for the year attributable to equity holders (18.61 ) (0.27 ) (18.88 ) (7.16 ) (7.16 )

Reclassification of comparati_2

Reclassification of comparatives (Tables)	12 Months Ended
	Jun. 30, 2023
Reclassification Of Comparatives [Abstract]
Disclosure in tabular form of reclassification of comparatives	30 June 2022 Reclassification 30 June 2022 Other assets 156 1,841 1,997 Borrowings — (1,841 ) (1,841 ) Current employee benefits 166 203 369 Non-current 319 (202 ) 117 Loss on remeasurement of contingent consideration 153 153 —  General and administrative expense (4,961 ) (153 ) (5,114 )

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of licensing revenue	2023 A$’000 2022 A$’000 2021 A$’000 Licensing revenue —  —  15,183
Summary of disaggregation of revenue from contracts with customers	The disaggregation of revenue from contracts with customers is as follows: 2023 A$’000 2022 A$’000 2021 A$’000 Geographical regions China —  —  10,006 Sweden —  —  5,177 —  —  15,183 Timing of revenue recognition Licensing revenue at a point in time —  —  15,183

Other income (Tables)

Other income (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of other income	2023 A$’000 2022 A$’000 2021 A$’000 Payroll tax rebate — — 2 Subsidies and grants — 10 — Bad debt recovery — 15 Other sundry income 1 1 25 2

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of expenses	2023 A$’000 2022 A$’000 2021 Loss before income tax includes the following specific Research and development EVT-801 program costs 5,060 2,520 1,073 Cantrixil program costs 5 12 429 Paxalisib program costs 5,618 13,713 11,404 Scientific Advisory Board costs 31 — — Employee benefits expense - salaries & wages and staff benefits 2,250 1,665 336 - superannuation 29 25 26 - share based payments 702 365 8 Total research & development (excluding amortisation) 13,695 18,300 13,276 Amortisation Paxalisib licensing agreement 1,084 1,084 1,084 Evotech licensing agreement 785 785 181 Total amortisation 1,869 1,869 1,265 Total research & development 15,564 20,169 14,541 Net foreign exchange loss Net foreign exchange loss 46 (2,154 ) 409 Rental expense relating to operating leases Minimum lease payments 152 73 93 Superannuation expense Defined contribution superannuation expense 131 138 138 Employee benefits expense G&A - salaries & wages and staff benefits 1,467 1,674 1,011 - superannuation 102 129 112 - share based payments 457 1,310 552 Total employee benefits expense G&A 2,026 3,113 1,675 Other Expenses Chinese With-Holding — — 931 Chinese Value Added Tax incurred on license transaction — — 538 — — 1,469

Income tax benefit_expense (Tab

Income tax benefit/expense (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of income tax benefit	2022 2021 2023 restated restated A$’000 A$’000 A$’000 Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (20,736 ) (25,382 ) (8,904 ) Tax at the statutory tax rate of 25% (2022 25% 202 1 (5,184 ) (6,345 ) (2,316 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: Research and Development claim — — — Amortisation of intangibles 467 467 348 Employee option plan 289 419 175 Gain/loss on revaluation of contingent consideration (847 ) 38 707 (5,275 ) (5,421 ) (1,086 ) Adjustment recognized for prior periods — 16 — Adjustment to deferred tax balances as a result of change in statutory tax rate — (113 ) (186 ) Tax losses and timing differences not recognized 5,004 5,150 788 Income tax benefit (271 ) (368 ) (484 ) 2023 2022 2021 Tax losses not recognized Unused tax losses for which no deferred tax asset has been recognized-Australia 120,412 96,519 70,896 Potential tax benefit 25.0% (202 2 1 30,103 24,130 17,724 Unused tax losses for which no deferred tax asset has been recognized US 4,305 2,380 2,038 Potential tax benefit at statutory tax rates 21%-US 904 500 428

Current assets - cash and cas_2

Current assets - cash and cash equivalents (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of cash and cash equivalents	2023 2022 A$’000 A$’000 Cash at bank and on hand 5,241 7,361 5,241 7,361

Trade and other receivables (Ta

Trade and other receivables (Tables)	12 Months Ended
	Jun. 30, 2023
Statement [line items]
Summary of current assets - trade and other receivables	2023 2022 A$’000 A$’000 Current assets Trade receivables 1 — GBM Agile deposit 3,753 — BAS receivables 104 51 Deposits held 41 40 3,899 91

Trade and other receivables -_2

Trade and other receivables - non-current (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of non-current assets - trade and other receivables non-current	2023 2022 A$’000 A$’000 Non-current GBM Agile deposit — 7,258 Corporate credit card deposit 43 43 43 7,301

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of current assets - other	Current assets 2022 2023 Reclassified A$’000 A$’000 Prepayments 1,632 1,997

Intangibles (Tables)

Intangibles (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of non-current assets - intangibles	Non-current Consolidated 2022 2023 A$’000 restated A$’000 Licensing agreement - Paxalisib 16,408 16,408 Less: Accumulated amortisation (7,251 ) (6,166 ) 9,157 10,242 Licensing agreement - EVT-801 9,813 9,813 Less: Accumulated amortisation (1,701 ) (916 ) 8,112 8,897 17,269 19,139
Summary of reconciliations of intangibles	EVT801 licensing agreement A$’000 Paxalisib licensing agreement A$’000 Total A$’000 Balance at 1 July 2021 as restated 9,682 11,326 21,008 Amortisation expense (785 ) (1,084 ) (1,869 ) Balance at 30 June 2022 restated 8,897 10,242 19,139 Amortisation expense (785 ) (1,085 ) (1,870 ) Balance at 30 June 2023 8,112 9,157 17,269

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Jun. 30, 2023
1 year or less [member]
Statement [line items]
Summary of trade and other payables	2023 2022 A$’000 A$’000 Trade payables 857 1,524 Accrued payables 3,472 2,235 4,329 3,759

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Jun. 30, 2023
Borrowings [abstract]
Schedule of borrowings	Current liabilities 2023 2022 Reclassified A$’000 A$’000 Insurance premium funding 1,796 1,841

Employee benefits (Tables)

Employee benefits (Tables)	12 Months Ended
	Jun. 30, 2023
1 year or less [member]
Statement [line items]
Summary of provisions	2023 2022 reclassified A$’000 Current Liabilities Employee benefits 201 — Annual leave 489 369 690 369 Non-Current Long service leave 59 117 749 486

Contingent consideration (Table

Contingent consideration (Tables)	12 Months Ended
	Jun. 30, 2023
Statement [line items]
Summary of liabilities - contingent consideration	2023 2022 Current Liabilities Contingent consideration – Paxalisib 750 —  Contingent consideration – EVT801 —  759 750 759 Non-current Contingent consideration - paxalisib 654 1,168 Contingent consideration – EVT801 5,467 7,041 6,121 8,209 6,871 8,968
Summary of reconciliation of contingent consideration	Consolidated 2022 2023 restated $ $ Contingent consideration at start of period (current and non-current) 8,968 11,094 Payment of EVT801 milestone — (2,364 ) Interest on unwinding of discount 594 567 Effect of exchange rates on contingent consideration 697 (329 ) Gain on remeasurement of contingent consideration (3,388 ) — 6,871 8,968

Deferred tax (Tables)

Deferred tax (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of non-current liabilities - deferred tax	2023 2022 A$’000 A$’000 Non-current Deferred tax liability associated with Licensing Agreement 2,289 2,560

Equity - contributed equity (Ta

Equity - contributed equity (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of equity - contributed equity	Consolidated 2023 2022 2023 2022 Shares Shares $ $ Ordinary shares - fully paid 228,029,114 138,755,376 97,452,246 84,480,249
Summary of movements in ordinary share capital	Movements in ordinary share capital Details Date Shares Issue price $ Balance 1 July 2021 132,012,209 80,290,062 Issued on conversion of options 15 December 2021 25,000 $ 0.6680 16,700 Conversion of Triaxial Convertible Note 5 May 2022 1,855,357 $ 0.2500 464,000 ATM issue of shares No. 1 24 May 2022 10,000 $ 0.8260 8,256 ATM issue of shares No. 2 2 June 2022 10,000 $ 0.8020 8,025 ATM issue of shares No. 3 6 June 2022 88,710 $ 0.8370 74,258 ATM issue of shares No. 4 9 June 2022 603,500 $ 0.8400 507,035 ATM issue of shares No. 5 14 June 2022 75,940 $ 0.8240 62,583 ATM issue of shares No. 6 15 June 2022 2,000 $ 0.8300 1,661 ATM issue of shares No. 7 20 June 2022 4,072,660 $ 0.8690 3,540,403 Less: share issue transaction costs — $ 0.0000 (492,735 ) Balance 30 June 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Shares issued to Scientific Advisory Board 14 September 2022 60,000 $ 0.2100 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 ATM issue of shares No. 18 11 January 2023 20,000 $ 0.1380 2,761 Professional and sophisticated investors placement – 1st tranche 16 January 2023 25,387,018 $ 0.1100 2,792,572 Professional and sophisticated investors placement – 2nd tranche 2 15,522,075 $ 0.1100 1,707,428 Share Placement Plan 3 March 2023 23,691,045 $ 0.1100 2,606,000 Less: share issue transaction costs — $ 0.0000 (400,750 ) Balance 228,029,114 97,452,246

Equity - reserves (Tables)

Equity - reserves (Tables)	12 Months Ended
	Jun. 30, 2023
Disclosure of reserves within equity [abstract]
Summary of tabular form of other reserves	2023 2022 A$’000 A$’000 Foreign currency reserve (742 ) (852 ) Share-based payments reserve 4,423 3,264 3,681 2,412

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Jun. 30, 2023
Statement [line items]
Summary of foreign currency risk	The carrying amount of the consolidated entity’s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: Assets Liabilities 2023 A$’000 2022 restated A$’000 2023 A$’000 2022 A$’000 US dollars 2,326 7,276 1,135 3,071 Euros — — 2,710 205 Singapore dollars — — 1 — 2,326 7,276 3,846 3,276
Summary of foreign currency risk sensitivity	If all currencies had strengthened and weakened AUD strengthened AUD weakened Consolidated - 2023 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (494 ) (494 ) (10 %) 494 494 Euros 10 % 271 271 (10 %) (271 ) (271 ) (223 ) (223 ) 223 223 AUD strengthened AUD weakened Consolidated – 2022 (restated) % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (420 ) (420 ) (10 %) 420 420 Euros 10 % 20 20 (10 %) (20 ) (20 ) (400 ) (400 ) 400 400
Summary of variable interest rate balances	As at the reporting date, the consolidated entity had the following variable interest rate balances: 2023 2022 Weighted average interest rate % Balance A$’000 Weighted average interest rate % Balance A$’000 Cash at bank and in hand 0.40 5,241 —  7,361 Net exposure to cash flow interest rate risk 5,241 7,361
Summary of remaining contractual maturities of financial instrument liabilities	2023 Weighted average % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining Non-derivatives Trade payables — 857 — — — 857 Accrued payables — 3,472 — — — 3,472 Contingent consideration — 750 4,303 3,099 — 8,152 Total non-derivatives 5,079 4,303 3,099 — 12,481 2022 restated Weighted average 1 year or less Between Between Over Remaining Non-derivatives Trade payables — 1,524 — — — 1,524 Accrued payables — 2,236 — — — 2,236 Contingent consideration — 759 8,338 795 — 9,892 Total non-derivatives 4,519 8,338 795 — 13,652

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of assets and liabilities, measured or disclosed at fair value	The following tables detail the consolidated entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3: Unobservable inputs for the asset or liability Consolidated - 2023 Level 1 A$’000 Level 2 A$’000 Level 3 A$’000 Total A$’000 Liabilities Contingent Consideration — — 1,404 1,404 Total liabilities — — 1,404 1,404 Consolidated - 2022 Liabilities Contingent Consideration — — 1,168 1,168 Total liabilities — — 1,168 1,168
Summary of movements in level 3 assets and liabilities	Movements in level 3 assets and liabilities during the current and previous financial year are set out below: Level 3 A$’000 Total A$’000 Consolidated Balance at 1 July 2021 1,015 1,015 Losses recognized in profit or loss 153 153 Balance at 30 June 2022 1,168 1,168 Losses recognized in profit or loss 236 236 Balance at 30 June 2023 1,404 1,404

Key management personnel disc_2

Key management personnel disclosures (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of compensation made to directors and other members of key management personnel	The aggregate compensation made to directors and other members of key management personnel (‘KMP’) of the consolidated entity is set out below: 2023 A$’000 2022 A$’000 2021 A$’000 Short-term employee benefits 3,148 2,589 1,574 Post-employment benefits 150 116 112 Share-based payments 1,046 1,560 617 4,344 4,265 2,303

Remuneration of auditors (Table

Remuneration of auditors (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of remuneration of auditors	During the financial year the following fees were paid or payable for services provided by BDO Audit Pty Ltd, the auditor of the Company: 2023 2022 2021 Audit services – BDO Audit Pty Ltd Audit or review of the financial statements 292 — — Other services BDO Audit Pty Ltd Comfort letter – ATM 18 — — 310 — — Audit services – Grant Thornton Audit Pty Ltd Audit or review of the financial statements — 155 151 Other services - Grant Thornton Audit Pty Ltd Comfort letter – ATM — 26 — — 181 151

Parent entity information (Tabl

Parent entity information (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Parent entity financial information	Set out below is the supplementary information about the parent entity. Parent 2023 2022 Statement of profit or loss and other comprehensive income Loss after income tax (20,863 ) (24,241 ) Total comprehensive income (20,863 ) (24,241 ) 2023 2022 Statement of financial position Total current assets 4,645 7,736 Total assets 21,915 26,875 Total current liabilities 7,003 2,931 Total liabilities 15,472 13,701 Equity Contributed equity 97,452 84,480 Reserves 4,423 3,264 Accumulated losses (95,432 ) (74,570 ) Total equity 6,443 13,174

Interests in subsidiaries (Tabl

Interests in subsidiaries (Tables)	12 Months Ended
	Jun. 30, 2023
Investments accounted for using equity method [abstract]
Summary of interest in subsidiaries	The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2: Ownership interest Name Principal place of business / Country of incorporation 2023 % 2022 % Kazia Laboratories Pty Ltd Australia 100.00 % 100.00 % Kazia Research Pty Ltd Australia 100.00 % 100.00 % Kazia Therapeutics Inc. United States of America 100.00 % 100.00 % Glioblast Pty Ltd Australia 100.00 % 100.00 % *Kazia Therapeutics (Hong Kong) Limited Hong Kong — 100.00 % *Kazia Therapeutics (Hong Kong) Limited was formally deregistered and dissolved on 10 March 2023.

Reconciliation of loss after _2

Reconciliation of loss after income tax to net cash used in operating activities (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Disclosure of reconciliation of profit or loss to operating cash flows	2023 2022 restated 2021 restated A$’000 A$’000 A$’000 Loss after income tax expense from continuing operations (20,465 ) (25,014 ) (8,420 ) Adjustments for: Depreciation & amortisation 1,869 1,869 1,265 Net fair value loss on financial assets — — — Share based payments 1,159 1,675 637 Foreign exchange differences 46 (2,154 ) 428 (Gain)/loss on remeasurement of contingent consideration (2,097 ) — 2,570 Change in operating assets & liabilities: (19,488 ) (23,624 ) (3,520 ) Decrease/(increase) in trade and other receivables 3,450 (7 ) (5,027 ) Decrease/(increase) in prepayments 365 (277 ) (1,182 ) Decrease/(increase) in trade and other payables 569 (528 ) 1,010 Decrease in deferred tax liability (271 ) (368 ) (484 ) Increase in other provisions 264 201 92 (Decrease)/increase in borrowings (45 ) 1,841 — Net cash used in operating activities (15,156 ) (22,762 ) (9,111 )

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of earnings per share	2023 A$’000 2022 restated 2021 restated A$’000 Earnings per share for loss from continuing operations Loss after income tax attributable to the owners of Kazia Therapeutics Limited (20,465 ) (25,014 ) (8,420 ) Loss after income tax attributable to the owners of Kazia Therapeutics Limited (20,465 ) (25,014 ) (8,420 ) Number Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 184,284,350 132,467,686 117,674,543 Weighted average number of ordinary shares used in calculating diluted earnings per share 184,284,350 132,467,686 117,674,543 Cents Cents Cents Basic earnings per share (11.23 ) (18.88 ) (7.16 ) Diluted earnings per share (11.23 ) (18.88 ) (7.16 )

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Jun. 30, 2023
Text block [abstract]
Summary of share-based payments	All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $1,159,125 (30 June 2022: $1,674,581) was recognized. Number of 2023 Weighted Number of Weighted Outstanding at the beginning of the financial year 8,655,500 $ 1.2826 4,219,000 $ 0.8911 Granted 7,930,000 $ 0.1785 4,800,000 $ 1.6115 Forfeited (1,550,000 ) $ 1.8977 — $ 0.0000 Exercised — $ 0.0000 (25,000 ) $ 0.6700 Expired (255,500 ) $ 1.8977 (338,500 ) $ 1.1123 Outstanding at the end of the financial year 14,780,000 $ 0.6292 8,655,500 $ 1.2826 Exercisable at the end of the financial year 6,483,333 $ 0.9572 3,180,500 $ 0.8770 2023 Tranche Grant date Expiry date Exercise Balance at Granted Exercised Expired / Balance at 1 07/08/2017 07/08/2022 $ 0.6700 15,500 — — (15,500 ) — 2 05/02/2018 05/02/2023 $ 0.7802 240,000 — — (240,000 ) — 3 13/11/2019 04/01/2024 $ 0.4925 1,200,000 — — — 1,200,000 4 13/01/2020 13/01/2025 $ 0.8812 200,000 — — (12,500 ) 187,500 5 09/11/2020 09/11/2024 $ 1.1320 1,200,000 — — — 1,200,000 6 09/11/2020 13/01/2025 $ 0.8812 800,000 — — (200,000 ) 600,000 7 04/01/2021 04/01/2025 $ 1.6900 200,000 — — (12,500 ) 187,500 8 09/09/2021 26/06/2026 $ 1.3650 100,000 — — — 100,000 9 16/11/2021 16/11/2025 $ 1.6900 1,000,000 — — (250,000 ) 750,000 10 16/11/2021 16/11/2025 $ 2.2400 1,500,000 — — (1,000,000 ) 500,000 11 16/11/2021 16/11/2026 $ 1.5600 800,000 — — — 800,000 12 01/02/2022 01/02/2027 $ 0.9400 800,000 — — — 800,000 13 01/02/2022 01/02/2027 $ 0.9400 500,000 — — (75,000 ) 425,000 14 24/05/2022 24/05/2027 $ 0.7800 100,000 — — — 100,000 15 03/03/2023 03/03/2027 $ 0.1500 — 3,930,000 — — 3,930,000 16 03/05/2023 03/05/2027 $ 0.1870 — 4,000,000 — — 4,000,000 8,655,500 7,930,000 — (1,805,500 ) 14,780,000 Weighted average exercise price $ 1.2826 $ 0.1785 $ 0.0000 $ 1.8977 $ 0.6292 At the end of the period the following outstanding options were vested and exercisable: - Options in tranches - Options in tranches - Options in tranches - Options in tranche - Options in tranches - Options in tranches - Options in tranche 15 were unvested - Options in tranche 16 were 33% vested The 2022 Tranche Grant date Expiry date Exercise Balance at Granted Exercised Expired / Balance at 1 05/09/2016 05/09/2021 $ 1.6300 50,000 — — (50,000 ) — 2 12/10/2016 17/10/2021 $ 1.5600 62,000 — — (62,000 ) — 3 31/10/2016 01/11/2021 $ 1.3800 12,500 — — (12,500 ) — 4 21/11/2016 23/11/2021 $ 1.3800 50,000 — — (50,000 ) — 5 07/08/2017 07/08/2022 $ 0.6700 87,000 — (25,000 ) (46,500 ) 15,500 6 05/02/2018 05/02/2023 $ 0.7800 320,000 — — (80,000 ) 240,000 7 04/01/2019 04/01/2024 $ 0.4925 37,500 — — (37,500 ) — 8 13/11/2019 13/11/2023 $ 0.4925 1,200,000 — — — 1,200,000 9 13/01/2020 13/01/2025 $ 0.8812 200,000 — — — 200,000 10 09/11/2020 09/11/2024 $ 1.1320 1,200,000 — — — 1,200,000 11 09/11/2020 09/11/2024 $ 0.8812 800,000 — — — 800,000 12 04/01/2021 04/01/2026 $ 1.6900 200,000 — — 200,000 13 09/09/2021 26/06/2026 $ 1.3700 — 100,000 — — 100,000 14 16/11/2021 16/11/2025 $ 1.6900 — 1,000,000 — — 1,000,000 15 16/11/2021 16/11/2025 $ 2.2400 — 1,500,000 — — 1,500,000 16 16/11/2021 16/11/2025 $ 1.5600 — 800,000 — — 800,000 17 01/02/2022 01/02/2027 $ 0.9400 — 800,000 — — 800,000 18 01/02/2022 01/02/2027 $ 0.9400 — 500,000 — — 500,000 19 24/05/2022 24/05/2027 $ 0.7800 — 100,000 — — 100,000 4,219,000 4,800,000 (25,000 ) (338,500 ) 8,655,500 Weighted average exercise price $ 0.8911 $ 1.6110 $ 0.6700 $ 1.1123 $ 1.2826 At the end of the period the following outstanding options were - Options in tranche 1- - Options in tranches 1 - 8 were vested and exercisable, apart from those in the above table which have expired - Options in tranche 9 -10 - Options in tranche 11 were vested and exercisable to 75% - Options in tranche 12-14 - Options in tranche 15-19 The weighted average remaining contractual life of options outstanding at 30 June 2022 is 3.048 years.
Summary of valuation for each tranche of options	Based on the above assumptions, the table below sets out the valuation for each tranche of options: Grant date Expiry date Share price at Grant Date Exercise Volatility (%) Dividend Risk free Rate (%) Fair value 13/11/2019 04/01/2024 $0.4100 $0.4925 74.50% — 1.95% $ 0.180 13/01/2020 13/01/2025 $0.6200 $0.8812 74.50% — 1.95% $ 0.340 09/11/2020 13/11/2024 $0.8900 $1.1320 90.00% — 0.10% $ 0.413 09/11/2020 13/01/2025 $0.8900 $0.8812 90.00% — 0.10% $ 0.503 04/01/2021 04/01/2025 $1.1850 $1.6900 90.00% — 0.19% $ 0.600 09/09/2021 21/06/2026 $1.4200 $1.3700 76.00% — 1.50% $ 0.880 16/11/2021 16/11/2025 $1.5700 $1.6900 76.00% — 1.50% $ 0.850 16/11/2021 16/11/2025 $1.5700 $2.2400 76.00% — 1.50% $ 0.750 16/11/2021 16/11/2026 $1.5700 $1.5600 76.00% — 1.50% $ 0.970 01/02/2022 01/02/2027 $0.9600 $0.9400 79.00% — 1.50% $ 0.590 24/05/2022 24/05/2027 $0.8000 $0.7800 44.00% — 2.95% $ 0.630 03/01/2023 03/03/2027 $0.1700 $0.1500 80.00% — 3.64% $ 0.10137 03/03/2023 03/03/2027 $0.1700 $0.1500 80.00% — 3.64% $ 0.10137 03/05/2023 03/05/2027 $0.1900 $0.1870 80.00% — 3.22% $ 0.11110

Significant accounting polici_3

Significant accounting policies - Additional Information (Detail)

1 Months Ended

12 Months Ended

Aug. 07, 2023 AUD ($)

Aug. 07, 2023 USD ($)

Jun. 30, 2023 AUD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 AUD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2021 AUD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

May 01, 2022 USD ($)

Jul. 01, 2021 AUD ($)

Jun. 30, 2020 AUD ($)

Disclosure of summary of significant accounting policies [line items]

Consolidated loss after income tax

$ 20,465,180

$ 25,014,055

$ 8,420,000

Net current asset position

3,207,572

2,720,664

Net cash outflows from operating activities

15,156,157

22,762,663

Consolidated cash in hand and at bank

5,241,197

7,361,112

27,587,000

$ 27,587,000

$ 8,764,000

Proceeds from issuing shares

$ 12,972,000

$ 3,726,000

$ 28,109,000

At The Market Equity Program [Member]

Disclosure of summary of significant accounting policies [line items]

Aggregate offering

$ 35,000,000

Proceeds from issuing shares

$ 4,203,221

$ 2,956,036

American Depository Shares [Member] | At The Market Equity Program [Member]

Disclosure of summary of significant accounting policies [line items]

Number of shares represented by one depositary receipt

10

Net amount eligible to be offered for issue

$ 27,800,000

$ 32,040,000

Major ordinary share transactions [member] | At The Market Equity Program [Member]

Disclosure of summary of significant accounting policies [line items]

Proceeds from the issuance of common stock

$ 1,540,918

$ 1,019,769

Licensing agreement for paxalisib [member]

Disclosure of summary of significant accounting policies [line items]

Remaining useful life,licensing agreement

15 years

15 years

Licensing agreement for EVT801 [member]

Disclosure of summary of significant accounting policies [line items]

Remaining useful life,licensing agreement

12.5 years

12.5 years

Critical Accounting Judgement_2

Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023
Disclosure of significant accounting judgments assumptions and estimates [abstract]
Percentage milestone trigger to account cost of asset conferred under license agreement	50%

Restatement of comparatives - S

Restatement of comparatives - Schedule of material restatement of financial position (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ 17,269	$ 19,139	$ 21,008	$ 21,008
Current contingent consideration	(750)	(759)	(791)
Non-Current contingent consideration		(8,209)	(10,303)
Contingent Consideration	(6,871)	(8,968)	(11,094)	(11,094)
Net Assets		18,274	37,853
Accumulated losses		(68,617)	(44,203)
Total equity		18,274	37,853
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		20,050		22,002
Current contingent consideration		(759)		(3,164)
Non-Current contingent consideration		(8,756)		(8,926)
Contingent Consideration		(9,515)		(12,091)
Net Assets		18,638		37,851
Accumulated losses		(68,253)		(44,205)
Total equity		18,638		37,851
Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(911)		(994)
Current contingent consideration				2,373
Non-Current contingent consideration		547		(1,377)
Contingent Consideration		547		997
Net Assets		(364)		2
Accumulated losses		(364)		2
Total equity		(364)		2
EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ 8,112	8,897		9,682
Gross carrying amount [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		26,221	26,221
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		27,266		27,265
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(1,045)		(1,044)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(7,082)	$ (5,213)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		(7,216)		(5,263)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill		$ 134		$ 50

Restatement of comparatives -_2

Restatement of comparatives - Schedule of material restatement of profit or loss and other comprehensive income (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)	$ (15,564,000)	$ (20,169,000)	$ (14,541,000)
General and administrative expense (foreign exchange impact)		(4,961,000)	(7,020,000)
Loss on revaluation of contingent consideration		(152,000)	(2,570,000)
Commercialisation expense	0	(127,000)	0
Loss before tax	(20,736,000)	(25,382,000)	(8,904,000)
Income tax benefit	271,000	368,000	484,000
Loss after tax	$ (20,465,180)	$ (25,014,055)	$ (8,420,000)
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders	$ (0.1123)	$ (0.1888)	$ (0.0716)
Diluted loss for the year attributable to equity holders	$ (0.1123)	$ (0.1888)	$ (0.0716)
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)		$ (20,252,000)	$ (14,541,000)
General and administrative expense (foreign exchange impact)		(4,511,000)	(7,022,000)
Loss on revaluation of contingent consideration		(152,000)	(2,570,000)
Commercialisation expense		(127,000)
Loss before tax		(25,016,000)	(8,906,000)
Income tax benefit		368,000	484,000
Loss after tax		$ (24,648,000)	$ (8,422,000)
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders		$ (0.1861)	$ (0.0716)
Diluted loss for the year attributable to equity holders		$ (0.1861)	$ (0.0716)
Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)		$ 83,000
General and administrative expense (foreign exchange impact)		(450,000)	$ 2,000
Loss before tax		(366,000)	2,000
Loss after tax		$ (366,000)	$ 2,000
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders		$ (0.0027)
Diluted loss for the year attributable to equity holders		$ (0.0027)

Restatement of comparatives - A

Restatement of comparatives - Additional Information (Detail)	Jun. 30, 2023
Restatement of comparatives [Abstract]
Incremental borrowing rate	6%

Reclassification of comparati_3

Reclassification of comparatives - Disclosure in tabular form of reclassification of comparatives (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2023	Jul. 01, 2021
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	$ 1,997		$ 1,632	$ 1,720
Borrowings	1,841		1,796	0
Current employee benefits	369		690	229
Non-current employee benefits	117		$ 59	$ 55
Loss on remeasurement of contingent consideration	(152)	$ (2,570)
Restated [member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	156
Current employee benefits	166
Non-current employee benefits	319
Loss on remeasurement of contingent consideration	153
General and administrative expense	(4,961)
Reclassification [Member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	1,841
Borrowings	(1,841)
Current employee benefits	203
Non-current employee benefits	(202)
Loss on remeasurement of contingent consideration	153
General and administrative expense	(153)
Reclassified [member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	1,997
Borrowings	(1,841)
Current employee benefits	369
Non-current employee benefits	117
General and administrative expense	$ (5,114)

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - Licensing Agreement [Member] - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2023	Jun. 30, 2021
Oasmia [Member]
Statement [line items]
Upfront payment received			$ 4,000
Simcere Pharmaceutical Group Limited [Member]
Statement [line items]
Upfront payment received	$ 11,000
Upfront payment received in cash	7,000
Upfront payment received in shares	$ 4,000
Premium on investment percentage	20%
Oasmia And Simcere Pharmaceutical Group [Member]
Statement [line items]
Revenue recognized out of consideration received from customers during the period		$ 0
Oasmia Pharmceutical AB And Sincere Pharmaceuticals Group Limited [Member]
Statement [line items]
Revenue from performance obligations satisfied or partially satisfied in previous periods			11,000
Commercial Milestone [Member] | Oasmia [Member]
Statement [line items]
Contingent milestone payment receivable			42,000
Commercial Milestone [Member] | Simcere Pharmaceutical Group Limited [Member]
Statement [line items]
Contingent milestone payment receivable			$ 281,000

Revenue - Summary of licensing

Revenue - Summary of licensing revenue (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of products and services [line items]
Revenue from contracts with customers	$ 0	$ 0	$ 15,183
Licensing revenue [Member]
Disclosure of products and services [line items]
Revenue from contracts with customers	$ 0	$ 0	$ 15,183

Revenue - Summary of disaggrega

Revenue - Summary of disaggregation of revenue from contracts with customers (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 0	$ 0	$ 15,183
Licensing revenue [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	0	0	15,183
Licensing revenue [Member] | Timing of revenue recognition [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	0	0	15,183
China [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	0	0	10,006
Sweden [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 0	$ 0	$ 5,177

Operating segments - Additional

Operating segments - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023 Segments
Disclosure of operating segments [abstract]
Number of operating segments	0

Other income - Summary of other

Other income - Summary of other income (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Material income and expense [abstract]
Payroll tax rebate			$ 2
Subsidies and grants		$ 10
Bad debt recovery		15
Other sundry income	$ 1
Other income	$ 1	$ 25	$ 2

Expenses - Summary of expenses

Expenses - Summary of expenses (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Loss before income tax includes the following specific
Scientific Advisory Board costs	$ 31
Employee benefits expense- salaries & wages and staff benefits	2,250	$ 1,665	$ 336
Employee benefits expense- superannuation	29	25	26
Employee benefits expense- share based payments	702	365	8
Amortisation	1,869	1,869	1,265
Net foreign exchange loss	46	(2,154)	409
Minimum lease payments	152	73	93
Defined contribution superannuation expense	131	138	138
Chinese With-Holding Tax incurred on license transaction			931
Chinese Value Added Tax incurred on license transaction			538
Total other expenses			1,469
Total research & development (excluding amortisation)	13,695	18,300	13,276
Total research & development	15,564	20,169	14,541
Employee benefits expense G&A
- salaries & wages and staff benefits	1,467	1,674	1,011
- superannuation	102	129	112
- share based payments	457	1,310	552
Total employee benefits expense G&A	2,026	3,113	1,675
EVT-801 program costs [member]
Loss before income tax includes the following specific
Research and development	5,060	2,520	1,073
Cantrixil program costs [member]
Loss before income tax includes the following specific
Research and development	5	12	429
Paxalisib program costs [member]
Loss before income tax includes the following specific
Research and development	5,618	13,713	11,404
Paxalisib licensing agreement [member]
Loss before income tax includes the following specific
Amortisation	1,084	1,084	1,084
Evotec Licensing Agreement [member]
Loss before income tax includes the following specific
Amortisation	$ 785	$ 785	$ 181

Income tax benefit_expense - Su

Income tax benefit/expense - Summary of Income tax benefit (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Numerical reconciliation of income tax benefit and tax at the statutory rate
Loss before income tax benefit	$ (20,736)	$ (25,382)	$ (8,904)
Tax at the statutory tax rate of 25% (2022 25% 2021 26%)	(5,184)	(6,345)	(2,316)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:
Research and Development claim			0
Amortisation of intangibles	467	467	348
Employee option plan	289	419	175
Gain/loss on revaluation of contingent consideration	(847)	38	707
Prior year tax losses not recognised now recouped	(5,275)	(5,421)	(1,086)
Adjustment recognized for prior periods		16
Adjustment to deferred tax balances as a result of change in statutory tax rate		(113)	(186)
Tax losses and timing differences not recognized	5,004	5,150	788
Income tax benefit	(271)	(368)	(484)
Australia [member]
Tax losses not recognized
Unused tax losses for which no deferred tax asset has been recognized	120,412	96,519	70,896
Potential tax benefit	30,103	24,130	17,724
US [member]
Tax losses not recognized
Unused tax losses for which no deferred tax asset has been recognized	4,305	2,380	2,038
Potential tax benefit	$ 904	$ 500	$ 428

Income tax benefit_expense - _2

Income tax benefit/expense - Summary of Income tax benefit (Parenthetical) (Detail)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	25%	25%	26%
Australia [member]
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	25%	25%	26%
US [member]
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	21%	21%	21%

Current assets - cash and cas_3

Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021	Jun. 30, 2020
Cash and cash equivalents [abstract]
Cash at bank and on hand	$ 5,241,000	$ 7,361,000
Cash and cash equivalents	$ 5,241,197	$ 7,361,112	$ 27,587,000	$ 27,587,000	$ 8,764,000

Trade and other receivables - S

Trade and other receivables - Summary of current assets - trade and other receivables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of financial assets [line items]
Current assets	$ 1
GBM Agile deposit	3,753
Trade and other receivables	3,899	$ 91	$ 84
BAS receivables [member]
Disclosure of financial assets [line items]
Other receivables	104	51
Deposits held [member]
Disclosure of financial assets [line items]
Other receivables	$ 41	$ 40

Trade and other receivables -_3

Trade and other receivables - non-current - Summary of non-current assets - trade and other receivables noncurrent (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 43	$ 7,301	$ 6,694
GBM agile deposit [member]
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current		7,258
Corporate credit card deposit [member]
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 43	$ 43

Other assets - Summary of curre

Other assets - Summary of current assets - other (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Statement of financial position [abstract]
Prepayments	$ 1,632	$ 1,997	$ 1,720

Intangibles - Summary of non-cu

Intangibles - Summary of non-current assets - intangibles (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ 17,269	$ 19,139	$ 21,008	$ 21,008
GDC licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	9,157	10,242
GDC licensing agreement [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	16,408	16,408
GDC licensing agreement [member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	(7,251)	(6,166)
Licensing Agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	8,112	8,897
Licensing Agreement [Member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	9,813	9,813
Licensing Agreement [Member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ (1,701)	$ (916)

Intangibles - Summary of reconc

Intangibles - Summary of reconciliations of intangibles (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 19,139	$ 21,008
Amortisation expense	(1,870)	(1,869)
Ending balance	17,269	19,139
Paxalisib licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	10,242	11,326
Amortisation expense	(1,085)	(1,084)
Ending balance	9,157	10,242
EVT801 licensing agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,897	9,682
Amortisation expense	(785)	(785)
Ending balance	$ 8,112	$ 8,897

Trade and other payables - Summ

Trade and other payables - Summary of current liabilities - trade and other payables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Trade and other payables [abstract]
Trade payables	$ 857	$ 1,524
Accrued payables	3,472	2,235
Total trade and other payables	$ 4,329	$ 3,759	$ 4,933

Borrowings - Schedule of borrow

Borrowings - Schedule of borrowings (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of detailed information about borrowings [line items]
Current borrowings	$ 1,796	$ 1,841	$ 0
Insurance Premium Funding [Member]
Disclosure of detailed information about borrowings [line items]
Current borrowings	$ 1,796	$ 1,841

Employee benefits - Summary of

Employee benefits - Summary of provision (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of defined benefit plans [abstract]
Employee benefits	$ 201
Annual leave	489	$ 369
Employee benefits	690	369	$ 229
Long service leave	59	117
Provisions for employee benefits	$ 749	$ 486

Contingent consideration - Summ

Contingent consideration - Summary of liabilities - contingent consideration (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021
Disclosure of contingent liabilities [line items]
Contingent consideration, current	$ 750	$ 759	$ 791
Contingent consideration, non-current	6,121	8,209	10,304
Contingent Consideration	6,871	8,968	$ 11,094	$ 11,094
Contingent consideration - paxalisib [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration, current	750
Contingent consideration, non-current	654	1,168
Contingent consideration – EVT801 [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration, current		759
Contingent consideration, non-current	$ 5,467	$ 7,041

Contingent consideration - Su_2

Contingent consideration - Summary of reconciliation of contingent consideration (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items]
Contingent Consideration	$ 8,968	$ 11,094
Payment of EVT801 milestone		(2,364)
Interest on unwinding of discount	594	567
Effect of exchange rates on contingent consideration	697	(329)
Gain on remeasurement of contingent consideration	(3,388)	0	$ 2,570
Contingent Consideration	$ 6,871	$ 8,968	$ 11,094

Contingent consideration - Addi

Contingent consideration - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023 AUD ($) Milestone	Jun. 30, 2023 EUR (€) Milestone	Jun. 30, 2022 AUD ($)	Jun. 30, 2022 EUR (€)
Disclosure of contingent liabilities [line items]
Milestone payments not booked	$ 492,703,722	€ 300,500,000	$ 456,063,136	€ 300,500,000
Milestone payment discount rate	20%	20%	15%	15%
Glioblast Pty Ltd [member]
Disclosure of contingent liabilities [line items]
Number of contingent milestone payments | Milestone	4	4
Milestone Two [member]
Disclosure of contingent liabilities [line items]
Contingent consideration | $	$ 1,250,000
Contingent consideration – EVT801 [Member]
Disclosure of contingent liabilities [line items]
Percentage of discount rate on milestone payments	7%	7%	6%	6%
Contingent consideration – EVT801 [Member] | Milestone Three [Member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	100%	100%	100%	100%
Contingent consideration – EVT801 [Member] | Milestone Four [member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	80%	80%	100%	100%
Contingent consideration – EVT801 [Member] | Milestone Five [member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	63%	63%	100%	100%

Deferred tax - Summary of non-c

Deferred tax - Summary of non-current liabilities - deferred tax (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Deferred tax assets and liabilities [abstract]
Deferred tax liability associated with Licensing Agreement - Non-current liabilities	$ 2,289	$ 2,560	$ 2,928

Equity - contributed equity - S

Equity - contributed equity - Summary of movements in ordinary share capital (Detail) - AUD ($)

12 Months Ended

Mar. 03, 2023

Feb. 18, 2023

Jan. 16, 2023

Jan. 11, 2023

Oct. 28, 2022

Oct. 07, 2022

Sep. 14, 2022

Sep. 13, 2022

Sep. 12, 2022

Aug. 12, 2022

Aug. 11, 2022

Aug. 10, 2022

Aug. 09, 2022

Aug. 08, 2022

Jul. 07, 2022

Jun. 30, 2022

Jun. 20, 2022

Jun. 15, 2022

Jun. 14, 2022

Jun. 09, 2022

Jun. 06, 2022

Jun. 02, 2022

May 24, 2022

May 05, 2022

Dec. 15, 2021

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2021

Disclosure of classes of share capital [line items]

Beginning Balance

$ 18,275,000

$ 37,853,000

$ 14,125,000

Issue of shares

13,373,000

4,202,000

273,000

Ending balance

$ 18,275,000

$ 12,050,000

$ 18,275,000

$ 37,853,000

Contributed equity [member]

Disclosure of classes of share capital [line items]

Beginning Balance

138,755,376

132,012,209

Ending Balance

138,755,376

228,029,114

138,755,376

132,012,209

Beginning Balance

$ 84,480,249

$ 80,290,062

$ 48,781,000

Issue of shares

13,373,000

4,202,000

273,000

Ending balance

$ 84,480,249

$ 97,452,246

$ 84,480,249

$ 80,290,062

Conversion of options [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.668

Conversion of options [member] | Contributed equity [member] | 15 December 2021 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

25,000

Issue of shares

$ 16,700

Scientific Advisory Board [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.21

Scientific Advisory Board [member] | Contributed equity [member] | 14 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

60,000

Issue of shares

$ 12,600

Share issue transaction costs [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0

$ 0

Share issue transaction costs [member] | Contributed equity [member]

Disclosure of classes of share capital [line items]

Issue of shares

$ (400,750)

$ (492,735)

Conversion of Triaxial Convertible Note [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.25

Conversion of Triaxial Convertible Note [Member] | Contributed equity [member] | 5 May 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,855,357

Issue of shares

$ 464,000

ATM issue of shares No. 1 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.826

ATM issue of shares No. 1 [Member] | Contributed equity [member] | 24 May 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 8,256

ATM issue of shares No. 2 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.802

ATM issue of shares No. 2 [Member] | Contributed equity [member] | 2 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 8,025

ATM issue of shares No. 3 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.837

ATM issue of shares No. 3 [Member] | Contributed equity [member] | 6 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

88,710

Issue of shares

$ 74,258

ATM issue of shares No. 4 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.84

ATM issue of shares No. 4 [Member] | Contributed equity [member] | 9 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

603,500

Issue of shares

$ 507,035

ATM issue of shares No. 5 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.824

ATM issue of shares No. 5 [Member] | Contributed equity [member] | 14 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

75,940

Issue of shares

$ 62,583

ATM issue of shares No. 6 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.83

ATM issue of shares No. 6 [Member] | Contributed equity [member] | 15 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

2,000

Issue of shares

$ 1,661

ATM issue of shares No. 7 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.869

ATM issue of shares No. 7 [Member] | Contributed equity [member] | 20 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

4,072,660

Issue of shares

$ 3,540,403

ATM issue of shares No. 8 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.7102

ATM issue of shares No. 8 [Member] | Contributed equity [member] | 7 July 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

573,370

Issue of shares

$ 407,201

ATM issue of shares No. 9 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.3316

ATM issue of shares No. 9 [Member] | Contributed equity [member] | 8 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

8,561,490

Issue of shares

$ 2,839,346

ATM issue of shares No. 10 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2723

ATM issue of shares No. 10 [Member] | Contributed equity [member] | 9 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 2,723

ATM issue of shares No. 11 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2465

ATM issue of shares No. 11 [Member] | Contributed equity [member] | 10 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

158,020

Issue of shares

$ 38,949

ATM issue of shares No. 12 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2413

ATM issue of shares No. 12 [Member] | Contributed equity [member] | 11 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

330,960

Issue of shares

$ 79,868

ATM issue of shares No. 13 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2469

ATM issue of shares No. 13 [Member] | Contributed equity [member] | 12 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,247,440

Issue of shares

$ 308,050

ATM issue of shares No. 14 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2211

ATM issue of shares No. 14 [Member] | Contributed equity [member] | 12 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

651,030

Issue of shares

$ 143,964

ATM issue of shares No. 15 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2187

ATM issue of shares No. 15 [Member] | Contributed equity [member] | 13 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

28,350

Issue of shares

$ 6,200

ATM issue of shares No. 16 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1789

ATM issue of shares No. 16 [Member] | Contributed equity [member] | 7 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

736,760

Issue of shares

$ 131,797

ATM issue of shares No. 17 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1865

ATM issue of shares No. 17 [Member] | Contributed equity [member] | 28 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

12,296,180

Issue of shares

$ 2,293,288

ATM issue of shares No. 18 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.138

ATM issue of shares No. 18 [Member] | Contributed equity [member] | 11 January 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

20,000

Issue of shares

$ 2,761

Professional and sophisticated investors placement – 1st tranche [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Professional and sophisticated investors placement – 1st tranche [Member] | Contributed equity [member] | 16 January 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

25,387,018

Issue of shares

$ 2,792,572

Professional and sophisticated investors placement – 2nd tranche [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Professional and sophisticated investors placement – 2nd tranche [Member] | Contributed equity [member] | 28 February 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

15,522,075

Issue of shares

$ 1,707,428

Share Placement Plan [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Share Placement Plan [Member] | Contributed equity [member] | 3 March 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

23,691,045

Issue of shares

$ 2,606,000

Equity - contributed equity -_2

Equity - contributed equity - Summary of equity - contributed equity (Detail) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of classes of share capital [abstract]
Ordinary shares - fully paid, shares	228,029,114	138,755,376
Ordinary shares - fully paid	$ 97,452,246	$ 84,480,249	$ 80,290,000

Equity - contributed equity - A

Equity - contributed equity - Additional Information (Detail)	Jun. 30, 2023 $ / shares
Disclosure of classes of share capital [abstract]
Fully paid ordinary shares par value	$ 0

Equity - reserves - Summary of

Equity - reserves - Summary of tabular form of other reserves (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of reserves within equity [abstract]
Foreign currency reserve	$ (742)	$ (852)
Share-based payments reserve	4,423	3,264
Other reserves	$ 3,681	$ 2,412	$ 1,301

Equity - dividends - Additional

Equity - dividends - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023 AUD ($)
Statement of changes in equity [abstract]
Dividends paid	$ 0

Financial instruments - Summary

Financial instruments - Summary of foreign currency risk (Detail) - Foreign currency risk [member] - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about financial instruments [line items]
Assets	$ 2,326	$ 7,276
Liabilities	3,846	3,276
US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Assets	2,326	7,276
Liabilities	1,135	3,071
Euros [member]
Disclosure of detailed information about financial instruments [line items]
Liabilities	2,710	$ 205
Singapore, Dollars
Disclosure of detailed information about financial instruments [line items]
Liabilities	$ 1

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about financial instruments [line items]
Net assets denominated in foreign currencies	$ 28,084,000	$ 35,889,000	$ 57,093,000
Cash and cash equivalents	5,241,197	7,361,112	$ 27,587,000	$ 27,587,000	$ 8,764,000
Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Net assets denominated in foreign currencies	$ 2,232,754	$ 3,999,645
Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Hypothetical percentage change in risk	10%	10%
Interest rate risk [member]
Disclosure of detailed information about financial instruments [line items]
Hypothetical percentage change in risk	1%	1%
Favourable/adverse effect on profit before tax and equity	$ 52,411	$ 73,611

Financial instruments - Summa_2

Financial instruments - Summary of foreign currency risk sensitivity (Detail) - Foreign currency risk [member] - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%	10%
Increase in market risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%	10%
Increase in market risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%	10%
Effect of increase in market risk on profit (loss) before tax [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ (223)	$ (400)
Effect of increase in market risk on profit (loss) before tax [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(494)	(420)
Effect of increase in market risk on profit (loss) before tax [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	271	20
Effect of increase in market risk on equity [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(223)	(400)
Effect of increase in market risk on equity [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(494)	(420)
Effect of increase in market risk on equity [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ 271	$ 20
Decrease in market risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	(10.00%)	(10.00%)
Decrease in market risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change	(10.00%)	(10.00%)
Effect of decrease in market risk on profit (loss) before tax [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ 223	$ 400
Effect of decrease in market risk on profit (loss) before tax [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	494	420
Effect of decrease in market risk on profit (loss) before tax [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(271)	(20)
Effect of decrease in market risk on equity [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	223	400
Effect of decrease in market risk on equity [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	494	420
Effect of decrease in market risk on equity [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ (271)	$ (20)

Financial instruments - Summa_3

Financial instruments - Summary of variable interest rate balances (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of financial instruments by type of interest rate [line items]
Cash at bank and in hand	$ 5,241	$ 7,361
Interest rate risk [member] | Variable interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Cash at bank and in hand	5,241	7,361
Net exposure to cash flow interest rate risk	$ 5,241	$ 7,361
Interest rate risk [member] | Variable interest rate [member] | Weighted average [member] | Cash at bank and in hand [member]
Disclosure of financial instruments by type of interest rate [line items]
Interest rate	0.40%

Financial instruments - Summa_4

Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade payables	$ 857	$ 1,524
Accrued payables	3,472	2,236
Contingent consideration	8,152	9,892
Total non-derivatives	12,481	13,652
1 year or less [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade payables	857	1,524
Accrued payables	3,472	2,236
Contingent consideration	750	759
Total non-derivatives	5,079	4,519
Between 1 and 2 years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Contingent consideration	4,303	8,338
Total non-derivatives	4,303	8,338
Between 2 and 5 years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Contingent consideration	3,099	795
Total non-derivatives	$ 3,099	$ 795

Fair value measurement - Summar

Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail) - AUD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	$ 6,121	$ 8,209	$ 10,304
Total liabilities	16,034	17,614	$ 19,240
At fair value [member]
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	1,404	1,168
Total liabilities	1,404	1,168
At fair value [member] | Level 3 [member]
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	1,404	1,168
Total liabilities	$ 1,404	$ 1,168

Fair value measurement - Summ_2

Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail) - At fair value [member] - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]
Balance Beginning	$ 1,168	$ 1,015
Losses recognized in profit or loss	236	153
Balance Ending	1,404	1,168
Level 3 [member]
Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]
Balance Beginning	1,168	1,015
Losses recognized in profit or loss	236	153
Balance Ending	$ 1,404	$ 1,168

Fair value measurement - Additi

Fair value measurement - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of fair value measurement of assets [line items]
Milestone payment discount rate	20%	15%
Bottom of range [member]
Disclosure of fair value measurement of assets [line items]
Milestone payment discount rate	57%
Top of range [member]
Disclosure of fair value measurement of assets [line items]
Milestone payment discount rate	60%

Key management personnel disc_3

Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Related party transactions [abstract]
Short-term employee benefits	$ 3,148	$ 2,589	$ 1,574
Post-employment benefits	150	116	112
Share-based payments	1,046	1,560	617
Key management personnel compensation	$ 4,344	$ 4,265	$ 2,303

Remuneration of auditors - Summ

Remuneration of auditors - Summary of remuneration of auditors (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
BDO Audit Pty Ltd [Member]
Auditor Remuneration [Line Items]
Audit or review of the financial statements	$ 292
Auditors Remuneration Other Services [Abstract]
Comfort letter – ATM	18
Auditors remuneration	310
Grant Thornton Audit Pty Ltd [Member]
Auditor Remuneration [Line Items]
Audit or review of the financial statements		155	151
Auditors Remuneration Other Services [Abstract]
Comfort letter – ATM		26
Auditors remuneration		$ 181	$ 151

Related party transactions - Ad

Related party transactions - Additional Information (Detail)	Jun. 30, 2023 AUD ($)
Disclosure of transactions between related parties [line items]
Trade receivables from related parties	$ 0
Trade payables to related parties	0
Loan to related parties	0
Loan from related parties	$ 0

Parent entity information - Sta

Parent entity information - Statement of profit or loss and other comprehensive income (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of parent entity information [line items]
Loss after income tax	$ (20,465,180)	$ (25,014,055)	$ (8,420,000)
Total comprehensive income	(20,355,000)	(24,979,000)	$ (8,418,000)
Parent [member]
Disclosure of parent entity information [line items]
Loss after income tax	(20,863,000)	(24,241,000)
Total comprehensive income	$ (20,863,000)	$ (24,241,000)

Parent entity information - S_2

Parent entity information - Statement of financial position (Detail) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021	Jun. 30, 2020
Disclosure of parent entity information [line items]
Total current assets	$ 10,772,000	$ 9,449,000	$ 29,391,000
Total assets	28,084,000	35,889,000	57,093,000
Total current liabilities	7,565,000	6,728,000	5,953,000
Total liabilities	16,034,000	17,614,000	19,240,000
Equity
Contributed equity	97,452,246	84,480,249	80,290,000
Reserves	3,681,000	2,412,000	1,301,000
Accumulated losses	(89,083,000)	(68,617,000)	(44,202,000)
Total equity	12,050,000	18,275,000	$ 37,853,000	$ 37,853,000	$ 14,125,000
Parent [member]
Disclosure of parent entity information [line items]
Total current assets	4,645,000	7,736,000
Total assets	21,915,000	26,875,000
Total current liabilities	7,003,000	2,931,000
Total liabilities	15,472,000	13,701,000
Equity
Contributed equity	97,452,000	84,480,000
Reserves	4,423,000	3,264,000
Accumulated losses	(95,432,000)	(74,570,000)
Total equity	$ 6,443,000	$ 13,174,000

Interests in subsidiaries - Sum

Interests in subsidiaries - Summary of interest in subsidiaries (Detail)		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Kazia Laboratories Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business		Australia
Country of incorporation		Australia
Ownership interest		100%	100%
Kazia Research Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business		Australia
Country of incorporation		Australia
Ownership interest		100%	100%
Kazia Therapeutics Inc [member]
Disclosure of subsidiaries [line items]
Principal place of business		United States of America
Country of incorporation		United States of America
Ownership interest		100%	100%
Glioblast Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business		Australia
Country of incorporation		Australia
Ownership interest		100%	100%
Kazia Therapeutics (Hong Kong) Limited [Member]
Disclosure of subsidiaries [line items]
Principal place of business	[1]	Hong Kong
Country of incorporation	[1]	Hong Kong
Ownership interest	[1]		100%
[1]Kazia Therapeutics (Hong Kong) Limited was formally deregistered and dissolved on 10 March 2023.

Reconciliation of loss after _3

Reconciliation of loss after income tax to net cash used in operating activities - Disclosure of reconciliation of profit or loss to operating cash flows (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of reconciliation of profit or loss to operating cash flows [Line Items]
Loss after income tax expense from continuing operations	$ (20,465,180)	$ (25,014,055)	$ (8,420,000)
Adjustments for:
Depreciation & amortisation	1,869,000	1,869,000	1,265,000
Net fair value loss on financial assets
Share based payments	1,159,000	1,675,000	637,000
Foreign exchange differences	46,000	(2,154,000)	428,000
(Gain)/loss on remeasurement of contingent consideration	(2,097,000)		2,570,000
Change in operating assets & liabilities:	(19,488,000)	(23,624,000)	(3,520,000)
Decrease/(increase) in trade and other receivables	3,450,000	(7,000)	(5,027,000)
Decrease/(increase) in prepayments	365,000	(277,000)	(1,182,000)
Decrease/(increase) in trade and other payables	569,000	(528,000)	1,010,000
Decrease in deferred tax liability	(271,000)	(368,000)	(484,000)
Increase in other provisions	264,000	201,000	92,000
(Decrease)/increase in borrowings	(45,000)	1,841,000
Net cash used in operating activities	$ (15,156,000)	$ (22,762,000)	$ (9,111,000)

Earnings per share - Summary of

Earnings per share - Summary of earnings per share (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [abstract]
Loss after income tax attributable to the owners of Kazia Therapeutics Limited	$ (20,465,180)	$ (25,014,055)	$ (8,420,000)
Loss after income tax attributable to the owners of Kazia Therapeutics Limited	$ (20,465,000)	$ (25,014,000)	$ (8,420,000)
Weighted average number of ordinary shares used in calculating basic earnings per share	184,284,350	132,467,686	117,674,543
Weighted average number of ordinary shares used in calculating diluted earnings per share	184,284,350	132,467,686	117,674,543
Basic earnings per share	$ (0.1123)	$ (0.1888)	$ (0.0716)
Diluted earnings per share	$ (0.1123)	$ (0.1888)	$ (0.0716)

Earnings per share - Additional

Earnings per share - Additional Information (Detail) - shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Unissued Shares Under Options [Member]
Earnings per share [line items]
Number of options that have been excluded from the calculations as they were antidilutive	14,780,000	8,655,500	4,219,000

Share-based payments - Addition

Share-based payments - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023 AUD ($)	Jun. 30, 2023	Jun. 30, 2023 shares	Jun. 30, 2022 AUD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Employee remuneration expense		$ 1,159,125			$ 1,674,581
Weighted average remaining contractual life of outstanding share options	2 years 11 months 28 days				3 years 17 days
Number of options issued to employees			7,930,000	7,930,000	4,800,000
Tranches 9 and 10 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable					50%
Tranche 11 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable					75%
Tranches 12 and 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable					25%
Tranche 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options issued to employees					1,000,000
Percentage of options going to vest			33%
Tranche 16 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested not vested and exercisable			33%		33%
Number of options issued to employees					800,000
Tranche 8 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable			50%
Tranches 4, 5, 7 and 9 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable			75%
Tranches 10 and 16 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable			33%
Tranches 11, 12, 13 and 14 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable			25%
Tranches 12 and 13 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options going to vest			25%

Share-based payments - Summary

Share-based payments - Summary of share-based payments (Detail)	12 Months Ended
	Jun. 30, 2023 $ / shares	Jun. 30, 2023 $ / shares	Jun. 30, 2023 $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the start of the year, share options			8,655,500		4,219,000
Granted, share options			7,930,000	7,930,000	4,800,000
Forfeited, share options			(1,550,000)
Exercised, share options					(25,000)
Expired / lapsed on termination of employment			(1,805,500)		(338,500)
Expired / lapsed on termination of employment			(255,500)		(338,500)
Balance at the end of the year, share options			14,780,000		8,655,500
Exercisable at the end of the financial year, share option	6,483,333	6,483,333	6,483,333	6,483,333	3,180,500
Balance at the start of the year, Weighted average exercise price		$ 1.2826			$ 0.8911
Granted, Weighted average exercise price		0.1785			1.611
Forfeited, Weighted average exercise price		1.8977			0
Exercised, Weighted average exercise price		0			0.67
Expired, Weighted average exercise price		1.8977			1.1123
Balance at the end of the year, Weighted average exercise price		0.6292			1.2826
Exercisable at the end of the financial year, Weighted average exercise price	$ 0.9572	0.9572	$ 0.9572	$ 0.9572	$ 0.877
Tranche 1 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date					05/09/2016
Expiry date					Sep. 05, 2021
Exercise price					$ 1.63
Balance at the start of the year, share options					50,000
Expired / lapsed on termination of employment					(50,000)
Tranche 2 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date					12/10/2016
Expiry date					Oct. 17, 2021
Exercise price					$ 1.56
Balance at the start of the year, share options					62,000
Expired / lapsed on termination of employment					(62,000)
Tranche 3 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date					31/10/2016
Expiry date					Nov. 01, 2021
Exercise price					$ 1.38
Balance at the start of the year, share options					12,500
Expired / lapsed on termination of employment					(12,500)
Tranche 4 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date					21/11/2016
Expiry date					Nov. 23, 2021
Exercise price					$ 1.38
Balance at the start of the year, share options					50,000
Expired / lapsed on termination of employment					(50,000)
Tranche 5 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	07/08/2017				07/08/2017
Expiry date	Aug. 07, 2022				Aug. 07, 2022
Exercise price		0.67			$ 0.67
Balance at the start of the year, share options			15,500		87,000
Exercised, share options					(25,000)
Expired / lapsed on termination of employment			(15,500)		(46,500)
Balance at the end of the year, share options					15,500
Tranche 6 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	05/02/2018				05/02/2018
Expiry date	Feb. 05, 2023				Feb. 05, 2023
Exercise price		0.7802			$ 0.78
Balance at the start of the year, share options			240,000		320,000
Expired / lapsed on termination of employment			(240,000)		(80,000)
Balance at the end of the year, share options					240,000
Tranche 7 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date					04/01/2019
Expiry date					Jan. 04, 2024
Exercise price					$ 0.4925
Balance at the start of the year, share options					37,500
Expired / lapsed on termination of employment					(37,500)
Tranche 8 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/11/2019				13/11/2019
Expiry date	Jan. 04, 2024				Nov. 13, 2023
Exercise price		0.4925			$ 0.4925
Balance at the start of the year, share options			1,200,000		1,200,000
Balance at the end of the year, share options			1,200,000		1,200,000
Tranche 9 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/01/2020				13/01/2020
Expiry date	Jan. 13, 2025				Jan. 13, 2025
Exercise price		0.8812			$ 0.8812
Balance at the start of the year, share options			200,000		200,000
Expired / lapsed on termination of employment			(12,500)
Balance at the end of the year, share options			187,500		200,000
Tranche 10 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020				09/11/2020
Expiry date	Nov. 09, 2024				Nov. 09, 2024
Exercise price		1.132			$ 1.132
Balance at the start of the year, share options			1,200,000		1,200,000
Balance at the end of the year, share options			1,200,000		1,200,000
Tranche 11 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020				09/11/2020
Expiry date	Jan. 13, 2025				Nov. 09, 2024
Exercise price		0.8812			$ 0.8812
Balance at the start of the year, share options			800,000		800,000
Expired / lapsed on termination of employment			(200,000)
Balance at the end of the year, share options			600,000		800,000
Tranche 12 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	04/01/2021				04/01/2021
Expiry date	Jan. 04, 2025				Jan. 04, 2026
Exercise price		1.69			$ 1.69
Balance at the start of the year, share options			200,000		200,000
Expired / lapsed on termination of employment			(12,500)
Balance at the end of the year, share options			187,500		200,000
Tranche 13 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/09/2021				09/09/2021
Expiry date	Jun. 26, 2026				Jun. 26, 2026
Exercise price		1.365			$ 1.37
Balance at the start of the year, share options			100,000
Granted, share options					100,000
Balance at the end of the year, share options			100,000		100,000
Tranche 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021				16/11/2021
Expiry date	Nov. 16, 2025				Nov. 16, 2025
Exercise price		1.69			$ 1.69
Balance at the start of the year, share options			1,000,000
Granted, share options					1,000,000
Expired / lapsed on termination of employment			(250,000)
Balance at the end of the year, share options			750,000		1,000,000
Tranche 15 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021				16/11/2021
Expiry date	Nov. 16, 2025				Nov. 16, 2025
Exercise price		2.24			$ 2.24
Balance at the start of the year, share options			1,500,000
Granted, share options					1,500,000
Expired / lapsed on termination of employment			(1,000,000)
Balance at the end of the year, share options			500,000		1,500,000
Tranche 16 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021				16/11/2021
Expiry date	Nov. 16, 2026				Nov. 16, 2025
Exercise price		1.56			$ 1.56
Balance at the start of the year, share options			800,000
Granted, share options					800,000
Balance at the end of the year, share options			800,000		800,000
Tranche 17 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022				01/02/2022
Expiry date	Feb. 01, 2027				Feb. 01, 2027
Exercise price		0.94			$ 0.94
Balance at the start of the year, share options			800,000
Granted, share options					800,000
Balance at the end of the year, share options			800,000		800,000
Tranche 18 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022				01/02/2022
Expiry date	Feb. 01, 2027				Feb. 01, 2027
Exercise price		0.94			$ 0.94
Balance at the start of the year, share options			500,000
Granted, share options					500,000
Expired / lapsed on termination of employment			(75,000)
Balance at the end of the year, share options			425,000		500,000
Tranche 19 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	24/05/2022				24/05/2022
Expiry date	May 24, 2027				May 24, 2027
Exercise price		0.78			$ 0.78
Balance at the start of the year, share options			100,000
Granted, share options					100,000
Balance at the end of the year, share options			100,000		100,000
Tranche 20 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/03/2023
Expiry date	Mar. 03, 2027
Exercise price		0.15
Granted, share options			3,930,000
Balance at the end of the year, share options			3,930,000
Tranche 21 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/05/2023
Expiry date	May 03, 2027
Exercise price		$ 0.187
Granted, share options			4,000,000
Balance at the end of the year, share options			4,000,000

Share-based payments - Summar_2

Share-based payments - Summary of valuation for each tranche of options (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Tranche 8 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/11/2019	13/11/2019
Expiry date	Jan. 04, 2024	Nov. 13, 2023
Share price at Grant Date	$ 0.41
Exercise price	$ 0.4925	$ 0.4925
Volatility (%)	74.50%
Dividend yield (%)
Risk free Rate	1.95%
Fair value per option	$ 0.18
Tranche 9 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/01/2020	13/01/2020
Expiry date	Jan. 13, 2025	Jan. 13, 2025
Share price at Grant Date	$ 0.62
Exercise price	$ 0.8812	$ 0.8812
Volatility (%)	74.50%
Dividend yield (%)
Risk free Rate	1.95%
Fair value per option	$ 0.34
Tranche 12 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	04/01/2021	04/01/2021
Expiry date	Jan. 04, 2025	Jan. 04, 2026
Share price at Grant Date	$ 1.185
Exercise price	$ 1.69	$ 1.69
Volatility (%)	90%
Dividend yield (%)
Risk free Rate	0.19%
Fair value per option	$ 0.6
Tranche 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Share price at Grant Date	$ 1.57
Exercise price	$ 1.69	$ 1.69
Volatility (%)	76%
Dividend yield (%)
Risk free Rate	1.50%
Fair value per option	$ 0.85
Tranche 15 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Share price at Grant Date	$ 1.57
Exercise price	$ 2.24	$ 2.24
Volatility (%)	76%
Dividend yield (%)
Risk free Rate	1.50%
Fair value per option	$ 0.75
Tranche 17 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022	01/02/2022
Expiry date	Feb. 01, 2027	Feb. 01, 2027
Share price at Grant Date	$ 0.96
Exercise price	$ 0.94	$ 0.94
Volatility (%)	79%
Dividend yield (%)
Risk free Rate	1.50%
Fair value per option	$ 0.59
Tranche 19 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	24/05/2022	24/05/2022
Expiry date	May 24, 2027	May 24, 2027
Share price at Grant Date	$ 0.8
Exercise price	$ 0.78	$ 0.78
Volatility (%)	44%
Dividend yield (%)
Risk free Rate	2.95%
Fair value per option	$ 0.63
Tranche 20 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/03/2023
Expiry date	Mar. 03, 2027
Share price at Grant Date	$ 0.17
Exercise price	$ 0.15
Volatility (%)	80%
Dividend yield (%)
Risk free Rate	3.64%
Fair value per option	$ 0.10137
Tranche 22 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020
Expiry date	Nov. 13, 2024
Share price at Grant Date	$ 0.89
Exercise price	$ 1.132
Volatility (%)	90%
Dividend yield (%)
Risk free Rate	0.10%
Fair value per option	$ 0.413
Tranche 23 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020
Expiry date	Jan. 13, 2025
Share price at Grant Date	$ 0.89
Exercise price	$ 0.8812
Volatility (%)	90%
Dividend yield (%)
Risk free Rate	0.10%
Fair value per option	$ 0.503
Tranche 24 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/09/2021
Expiry date	Jun. 21, 2026
Share price at Grant Date	$ 1.42
Exercise price	$ 1.37
Volatility (%)	76%
Dividend yield (%)
Risk free Rate	1.50%
Fair value per option	$ 0.88
Tranche 25 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021
Expiry date	Nov. 16, 2026
Share price at Grant Date	$ 1.57
Exercise price	$ 1.56
Volatility (%)	76%
Dividend yield (%)
Risk free Rate	1.50%
Fair value per option	$ 0.97
Tranche 26 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/01/2023
Expiry date	Mar. 03, 2027
Share price at Grant Date	$ 0.17
Exercise price	$ 0.15
Volatility (%)	80%
Dividend yield (%)
Risk free Rate	3.64%
Fair value per option	$ 0.10137
Tranche 27 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/05/2023
Expiry date	May 03, 2027
Share price at Grant Date	$ 0.19
Exercise price	$ 0.187
Volatility (%)	80%
Dividend yield (%)
Risk free Rate	3.22%
Fair value per option	$ 0.1111

Subsequent events - Additional

Subsequent events - Additional Information (Detail)			1 Months Ended		12 Months Ended
	Oct. 11, 2023	Jul. 01, 2023	Aug. 07, 2023 AUD ($) shares	Aug. 07, 2023 USD ($) shares	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of shares | $					$ 12,972,000	$ 3,726,000	$ 28,109,000
Resignation of chairman [member]
Cash flows from (used in) financing activities [abstract]
Number of shares outstanding | shares			236,349,374	236,349,374
Proceeds from issue of shares			$ 1,540,918	$ 1,019,769
Fast Track Designation from US FDA for paxalisib [member] | Bottom of range [member]
Cash flows from (used in) financing activities [abstract]
Response rate for radiotherapy		20%
Fast Track Designation from US FDA for paxalisib [member] | Top of range [member]
Cash flows from (used in) financing activities [abstract]
Response rate for radiotherapy		40%
Delisting Of Shares [Member] | ASX [member]
Cash flows from (used in) financing activities [abstract]
Minimum notice period to be given to shareholders regarding delisting	1 month